Document:

exv10w1

Exhibit 10.1

2,250,000 Units

THERMOGENESIS CORP.

PLACEMENT AGENT AGREEMENT

March 4, 2011

HOULIHAN LOKEY CAPITAL, INC.

One Sansome Street, Suite 1700

San Francisco, CA 94104

Dear Sirs:

     1. INTRODUCTION. ThermoGenesis Corp., a Delaware corporation (the “Company”), proposes to
issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent
Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A
attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein
(each a “Purchaser” and collectively, the “Purchasers”), up to an aggregate of 2,250,000 units (the
“Units”) with each Unit consisting of (i) one share of common stock, $0.001 par value per share
(the “Common Stock”), of the Company (each, a “Share,” and, collectively, the “Shares”), and (ii)
one warrant to purchase one-half of one share of Common Stock (each, a “Warrant” and, collectively,
the “Warrants”). The terms and conditions of the Warrants are set forth in the form of Exhibit B
attached to the Subscription Agreements. The Units will not be issued or certificated. The Shares
and Warrants are immediately separable and will be issued separately. The Company hereby
confirms its agreement with Houlihan Lokey Capital, Inc. (the “Agent”) to act as the placement
agent in accordance with the terms and conditions hereof.

     2. AGREEMENT TO ACT AS PLACEMENT AGENT; PLACEMENT OF UNITS. On the basis of the
representations, warranties and agreements of the Company herein contained, and subject to all the
terms and conditions of this Agreement:

          2.1 The Company has authorized and hereby acknowledges that the Agent has acted as its
exclusive agent to solicit offers for the purchase of all or part of the Units from the Company in
connection with the proposed offering of the Units (the “Offering”). Until the Closing Date (as
defined in Section 4 hereof), the Company shall not, without the prior written consent of
the Agent, solicit or accept offers to purchase Units otherwise than through the Agent. The Company
acknowledges and agrees that the Agent may utilize the expertise of its affiliates and partners in
connection with the Agent’s placement agent activities.

          2.2 The Company hereby acknowledges that the Agent, as agent of the Company, used its
commercially reasonable efforts to solicit offers to purchase the Units from the Company on the
terms and subject to the conditions set forth in the Prospectus (as defined below). The Agent shall
use commercially reasonable efforts to assist the Company in obtaining performance by each
Purchaser whose offer to purchase Units was solicited by the Agent and accepted by the Company,
including the prompt execution by each Purchaser of a Subscription

 

 

Agreement to purchase Units, but the Agent shall not, except as otherwise provided in this
Agreement, be obligated to disclose the identity of any potential purchaser or have any liability
to the Company in the event any such purchase is not consummated for any reason. Under no
circumstances will the Agent be obligated to underwrite or purchase any Units for its own account
and the Company acknowledges and agrees that, in soliciting purchases of Units, the Agent has
acted, and is acting, solely as the Company’s agent, and not as a principal.

          2.3 Subject to the provisions of this Section 2, offers for the purchase of Units were
and shall be solicited by the Agent as agent for the Company at such times and in such amounts as
the Agent deems advisable. The Agent shall communicate to the Company, orally or in writing, each
reasonable offer to purchase Units received by it as agent of the Company. The Company shall have
the sole right to accept offers to purchase the Units and may reject any such offer, in whole or in
part. The Agent shall have the right, in its discretion reasonably exercised, without notice to the
Company, to reject any offer to purchase Units received by it, in whole or in part, and any such
rejection shall not be deemed a breach of this Agreement.

          2.4 The Units are being sold to the Purchasers at a price of $2.00 per Unit. The purchases of
the Units by the Purchasers shall be evidenced by the execution of Subscription Agreements by each
of the Purchasers and the Company.

          2.5 As compensation for services rendered, (i) on the Closing Date (as defined in Section
4 hereof), the Company shall pay to the Agent by wire transfer of immediately available funds
to an account or accounts designated by the Agent, an aggregate amount equal to 8.0% of
the gross proceeds received by the Company from the sale of the Units on such Closing Date (the
“Share Placement Fee”), and (ii) on each date of delivery of Warrant Shares in respect of the
Warrant, the Company shall pay to the Agent by wire transfer of immediately available funds to an
account or accounts designated by the Agent, an aggregate amount equal to 8.0% of the gross
proceeds received by the Company (together with the Share Placement Fee, the “Placement Fee”) from
the exercise of the Warrants on such date(s) of delivery.

          2.6 No Units which the Company has agreed to sell pursuant to this Agreement and the
Subscription Agreements shall be deemed to have been purchased and paid for, or sold by the
Company, until such Units shall have been delivered to the Purchaser thereof against payment by
such Purchaser. If the Company shall default in its obligations to deliver Units to a Purchaser
whose offer it has accepted, the Company shall indemnify and hold the Agent harmless against any
loss, claim, damage or expense arising from or as a result of such default by the Company in
accordance with the procedures set forth in Section 8(c) herein.

     3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to, and
agrees with, the Agent and the Purchasers that:

          (a) The Company has prepared and filed in conformity with the requirements of the Securities
Act of 1933, as amended (the “Securities Act”), and published rules and regulations thereunder (the
“Rules and Regulations”) adopted by the Securities and Exchange Commission (the “Commission”) a
“shelf” Registration Statement (as hereinafter defined) on Form S-3 (File No. 333-171563), which
became effective as of January 19, 2011 (the “Effective Date”), including a base prospectus
relating to the securities registered pursuant to such Registration Statement (the “Base
Prospectus”), and such amendments and supplements thereto as may have been required to the date of
this Agreement. The term “Registration Statement” as

 

 

used in this Agreement means the registration statement described in the foregoing sentence
(including all exhibits, financial schedules and all documents and information deemed to be a part
of the Registration Statement pursuant to Rule 430A of the Rules and Regulations), as amended
and/or supplemented to the date of this Agreement, including the Base Prospectus. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the
effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus
has been issued by the Commission and no proceedings for that purpose have been instituted or, to
the best of the Company’s knowledge, are threatened by the Commission. The Company, if required by
the Rules and Regulations of the Commission, will file the Prospectus (as defined below), with the
Commission pursuant to Rule 424(b) of the Rules and Regulations. The term “Prospectus” as used in
this Agreement means the Prospectus, in the form in which it is to be filed with the Commission
pursuant to Rule 424(b) of the Rules and Regulations, or, if the Prospectus is not to be filed with
the Commission pursuant to Rule 424(b), the Prospectus in the form included as part of the
Registration Statement as of the Effective Date, except that if any revised prospectus or
prospectus supplement shall be provided to the Agent by the Company for use in connection with the
offering and sale of the Units which differs from the Prospectus (whether or not such revised
prospectus or prospectus supplement is required to be filed by the Company pursuant to Rule 424(b)
of the Rules and Regulations), the term “Prospectus” shall refer to such revised prospectus or
prospectus supplement, as the case may be, from and after the time it is first provided to the
Agent for such use. Any preliminary prospectus or prospectus subject to completion included in the
Registration Statement or filed with the Commission pursuant to Rule 424 of the Rules and
Regulations is hereafter called a “Preliminary Prospectus.” Any reference herein to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to
and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which
were filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on or before
the last to occur of the Effective Date, the date of the Preliminary Prospectus, or the date of the
Prospectus, and any reference herein to the terms “amend,” “amendment,” or “supplement” with
respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed
to refer to and include (i) the filing of any document under the Exchange Act after the Effective
Date, the date of such Preliminary Prospectus or the date of the Prospectus, as the case may be,
which is incorporated by reference and (ii) any such document so filed. If the Company has filed an
abbreviated registration statement to register additional securities pursuant to Rule 462(b) under
the Rules and Regulations (the “462(b) Registration Statement”), then any reference herein to the
Registration Statement shall also be deemed to include such 462(b) Registration Statement.

          (b) As of the Applicable Time (as defined below) and as of the Closing Date, neither (i) any
General Use Free Writing Prospectus (as defined below) issued at or prior to the Applicable Time,
and the Pricing Prospectus (as defined below), all considered together (collectively, the “General
Disclosure Package”), (ii) any individual Limited Use Free Writing Prospectus (as defined below)
issued at or prior to the Applicable Time, nor (iii) the bona fide electronic road show (as defined
in Rule 433(h)(5) of the Rules and Regulations), if any, that has been made available without
restriction to any person, when considered together with the General Disclosure Package, included
or will include, any untrue statement of a material fact or omitted or as of the Closing Date will
omit, to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; provided, however, that the Company
makes no representations or warranties as to information contained in or omitted from any Issuer
Free Writing Prospectus or the Pricing

 

 

Prospectus, in reliance upon, and in conformity with, written information furnished to the
Company by the Agent specifically for inclusion therein, which information the parties hereto agree
is limited to the Agent’s Information (as defined in Section 17). As used in this
paragraph (b) and elsewhere in this Agreement:

     “Applicable Time” means 11:30 P.M., New York time, on the date of this Agreement.

     “General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is
identified on Exhibit B to this Agreement.

     “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in
Rule 433 of the Rules and Regulations relating to the Units in the form filed or required to be
filed with the Commission or, if not required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g) of the Rules and Regulations.

     “Limited Use Free Writing Prospectuses” means any Issuer Free Writing Prospectus that is not a
General Use Free Writing Prospectus.

     “Pricing Prospectus” means the Preliminary Prospectus, if any, and the Base Prospectus, each
as amended and supplemented immediately prior to the Applicable Time, including any document
incorporated by reference therein and any prospectus supplement deemed to be a part thereof,
including the final prospectus supplement dated the date hereof.

          (c) No order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free
Writing Prospectus or the Prospectus relating to the Offering has been issued by the Commission,
and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been
instituted or, to the best of the Company’s knowledge, threatened by the Commission, and any
Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the
requirements of the Securities Act and the Rules and Regulations, and did not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; provided, however, that the Company makes no representations or warranties as
to information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in
conformity with, written information furnished to the Company by the Agent specifically for
inclusion therein, which information the parties hereto agree is limited to the Agent’s Information
(as defined in Section 17).

          (d) At the respective times the Registration Statement and any amendments thereto became or
become effective, at the date of this Agreement and at the Closing Date, each Registration
Statement and any amendments thereto conformed and will conform in all material respects to the
requirements of the Securities Act and the Rules and Regulations and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Prospectus and any
amendments or supplements thereto, at the time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to
the requirements of the Securities Act and the Rules and Regulations and did not and will not
contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that the

 

 

foregoing representations and warranties in this paragraph (d) shall not apply to
information contained in or omitted from the Registration Statement or the Prospectus, or any
amendment or supplement thereto, in reliance upon, and in conformity with, written information
furnished to the Company by the Agent specifically for inclusion therein, which information the
parties hereto agree is limited to the Agent’s Information (as defined in Section 17). The
Prospectus contains all required information under the Securities Act with respect to the Units and
the distribution of the Units.

          (e) Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent
times through the completion of the public offer and sale of the Units or until any earlier date
that the Company notified or notifies the Agent as described in Section 5(e), did not, does
not and will not include any information that conflicted, conflicts or will conflict with the
information contained in the Registration Statement, Pricing Prospectus or the Prospectus,
including any document incorporated by reference therein and any prospectus supplement deemed to be
a part thereof that has not been superseded or modified, or includes an untrue statement of a
material fact or omitted or would omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The foregoing sentence does not apply to statements in or omissions
from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written
information furnished to the Company by the Agent specifically for inclusion therein, which
information the parties hereto agree is limited to the Agent’s Information (as defined in
Section 17).

          (f) The documents incorporated by reference in the Registration Statement, the Prospectus or
the General Disclosure Package, as the case may be, when they became effective or were filed with
the Commission, as the case may be, conformed in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission
thereunder and none of such documents contained any untrue statement of a material fact or omitted
to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and any
further documents so filed and incorporated by reference in the Registration Statement, the
Prospectus or the General Disclosure Package, as the case may be, when such documents become
effective or are filed with the Commission, as the case may be, will conform in all material
respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the
rules and regulations of the Commission thereunder and will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not
misleading.

          (g) At the time of filing the initial Registration Statement, any 462(b) Registration
Statement and any post-effective amendments thereto, and at the date hereof, the Company was not,
and the Company currently is not, an “ineligible issuer,” as defined in Rule 405 of the Rules and
Regulations. The Company has not, directly or indirectly, distributed and will not distribute any
offering material in connection with the Offering other than any Preliminary Prospectus, the
Prospectus and other materials, if any, permitted under the Securities Act and consistent with
Section 5(b) below. The Company will file with the Commission all Issuer Free Writing
Prospectuses (other than a “road show,” as described in Rule 433(d)(8) of the

 

 

Rules and Regulations), if any, in the time and manner required under Rule 433(d) of the Rules
and Regulations.

          (h) The Company and each of its subsidiaries (as defined in Section 15) has been duly
organized and is validly existing as corporations or other legal entities in good standing (or the
foreign equivalent thereof) under the laws of their respective jurisdictions of organization. The
Company and each of its subsidiaries is duly qualified to do business and is in good standing as
foreign corporations or other legal entities in each jurisdiction in which their respective
ownership or lease of property or the conduct of their respective businesses require such
qualification and have all power and authority necessary to own or hold their respective properties
and to conduct the businesses in which each is engaged, except where the failure to so qualify or
have such power or authority (i) would not have, singularly or in the aggregate, a material adverse
effect on the condition (financial or otherwise), results of operations, assets, business,
liquidity or prospects of the Company and its subsidiaries taken as a whole, or (ii) impair in any
material respect the ability of the Company to perform its obligations under this Agreement or to
consummate any transactions contemplated by this Agreement (any such effect as described in clauses
(i) or (ii), a “Material Adverse Effect”). The Company does not own or control, directly or
indirectly, any corporation, partnership, limited liability partnership, limited liability company,
association or other entity.

          (i) The Company has the full right, power and authority to enter into this Agreement, each of
the Subscription Agreements and the Warrants, and to perform and to discharge its obligations
hereunder and thereunder; and each of this Agreement, each of the Subscription Agreements and each
of the Warrants has been duly authorized, executed and delivered by the Company, and constitutes a
valid and binding obligation of the Company enforceable in accordance with its terms; except that
such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other similar laws, now or hereafter in effect, affecting creditors’ rights generally.

          (j) The Shares to be issued and sold by the Company to the Purchasers hereunder and under the
Subscription Agreements and the shares of Common Stock issuable upon exercise of the Warrants (the
“Warrant Shares”) have been duly and validly authorized and, when the Shares have been issued and
delivered against payment therefor as provided herein and the Subscription Agreements and when the
Warrant Shares have been delivered and paid for in accordance with the Warrants, all such shares of
Common Stock will be duly and validly issued, fully paid and nonassessable and free of any
preemptive or similar rights and will conform to the description thereof contained in the General
Disclosure Package and the Prospectus.

          (k) The Company has an authorized capitalization as set forth in the General Disclosure
Package, and all of the issued shares of capital stock of the Company have been duly and validly
authorized and issued, are fully paid and non-assessable, have been issued in compliance with
federal and state securities laws, and conform to the description thereof contained in the General
Disclosure Package. None of the outstanding shares of Common Stock was issued in violation of any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase
securities of the Company. As of the date set forth in the General Disclosure Package, there were
no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other
rights to purchase, or equity or debt securities convertible

 

 

into or exchangeable or exercisable for, any capital stock of the Company or any of its
subsidiaries other than those accurately described in the General Disclosure Package. Since such
date, the Company has not issued any securities other than Common Stock issued pursuant to the
exercise of warrants or upon the exercise of stock options previously outstanding under the
Company’s stock option plans and the issuance of Common Stock pursuant to employee stock purchase
plans, except for the issuance of an aggregate of 70,000 shares of restricted Common Stock on
November 3, 2010 pursuant to that certain International Distributor Agreement, dated November 3,
2010, between the Company and Nanshan Memorial Medical Institute.

          (l) The Company has no subsidiaries.

          (m) The execution, delivery and performance of this Agreement, the Subscription Agreements and
the Warrants by the Company, the issue and sale of the Units by the Company and the consummation of
the transactions contemplated hereby and thereby will not (with or without notice or lapse of time
or both) conflict with or result in a breach or violation of any of the terms or provisions of,
constitute a default or Debt Repayment Triggering Event (as defined below) under, give rise to any
right of termination or other right or the cancellation or acceleration of any right or obligation
or loss of a benefit under, or give rise to the creation or imposition of any lien, encumbrance,
security interest, claim or charge upon any property or assets of the Company or any subsidiary
pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company or any of its subsidiaries is a party or by which the Company or
any of its subsidiaries is bound or to which any of the property or assets of the Company or any of
its subsidiaries is subject, nor will such actions result in any violation of the provisions of the
charter or by-laws (or analogous governing instruments, as applicable) of the Company or any of its
subsidiaries or any law, statute, rule, regulation, judgment, order or decree of any court or
governmental agency or body, domestic or foreign, having jurisdiction over the Company or any of
its subsidiaries or any of their properties or assets. A “Debt Repayment Triggering Event” means
any event or condition that gives, or with the giving of notice or lapse of time would give the
holder of any note, debenture or other evidence of indebtedness (or any person acting on such
holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its subsidiaries.

          (n) Except for the registration of the securities offered in the Offering under the Securities
Act and such consents, approvals, authorizations, registrations or qualifications as may be
required under the Exchange Act and applicable state or foreign securities laws, the Financial
Industry Regulatory Authority, Inc. (“FINRA”) and the Nasdaq Stock Market, LLC (“Nasdaq”) in
connection with the offering and sale of the Units by the Company, no consent, approval,
authorization or order of, or filing, qualification or registration with, any court or governmental
agency or body, foreign or domestic, which has not been made, obtained or taken and is not in full
force and effect, is required for the execution, delivery and performance of this Agreement, the
Subscription Agreements and the Warrants by the Company, the offer or sale of the Units or the
consummation of the transactions contemplated hereby and thereby.

          (o) Ernst & Young LLP, who have audited the Company’s consolidated financial statements for
the years ended June 30, 2010 and 2009 and for the three years in the period ended June 30, 2010
and the related schedule and have performed reviews in accordance with Statement on Auditing
Standards No. 100 as of and for the three- and six-month periods

 

 

ended December 31, 2010 and 2009 and as of and for the three month periods ended September 30,
2010 and 2009 incorporated by reference in the Registration Statement, the General Disclosure
Package and the Prospectus, and have audited the Company’s internal control over financial
reporting, is an independent registered public accounting firm as required by the Securities Act
and the Rules and Regulations and the Public Company Accounting Oversight Board (United States)
(the “PCAOB”). During the three year period immediately preceding the date of this Agreement, Ernst
& Young LLP has not performed any “prohibited activities” (as defined in Section 10A of the
Exchange Act) on behalf of the Company and Ernst & Young LLP has not been engaged by the Company to
perform any “prohibited activities” (as defined in Section 10A of the Exchange Act) at any time on
or after the date hereof.

          (p) The financial statements, together with the related notes and schedules, included or
incorporated by reference in the General Disclosure Package, the Prospectus and in the Registration
Statement fairly present the financial position and the results of operations and changes in
financial position of the Company and its consolidated subsidiaries at the respective dates or for
the respective periods therein specified. Such statements and related notes and schedules have been
prepared in accordance with the generally accepted accounting principles in the United States
(“GAAP”) applied on a consistent basis throughout the periods involved except as may be set forth
in the related notes included or incorporated by reference in the General Disclosure Package. The
financial statements, together with the related notes and schedules, included or incorporated by
reference in the General Disclosure Package, the Prospectus and in the Registration Statement
comply in all material respects with the Securities Act, the Exchange Act, and the Rules and
Regulations and the rules and regulations under the Exchange Act. No other financial statements or
supporting schedules or exhibits, including, without limitation, any pro forma or as adjusted
financial information, are required by the Securities Act or the Rules and Regulations to be
described, or included or incorporated by reference in the General Disclosure Package, the
Prospectus or the Registration Statement.

          (q) None of the Company or any of its subsidiaries has sustained, since the date of the latest
audited financial statements included or incorporated by reference in the General Disclosure
Package, any material loss or interference with its business from fire, explosion, flood or other
calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree; and, since such date, there has not been any change in the capital stock
(other than Common Stock of the Company issued pursuant to the exercise of warrants or upon the
exercise of stock options previously outstanding under the Company’s stock option plans and the
issuance of Common Stock pursuant to employee stock purchase plans) or long-term debt of the
Company or any of its subsidiaries, or any material adverse change, or any development involving a
prospective material adverse change, in or affecting the business, assets, general affairs,
management, financial position, prospects, liquidity, stockholders’ equity or results of operations
of the Company and its subsidiaries taken as a whole, otherwise than as set forth in the General
Disclosure Package.

          (r) Except as set forth in the General Disclosure Package, there is no legal or governmental
action, suit, claim or proceeding pending to which the Company or any of its subsidiaries is a
party or of which any property or assets of the Company or any of its subsidiaries is the subject
that is required to be described in the Registration Statement, the General Disclosure Package or
the Prospectus or a document incorporated by reference therein and is not described therein, or
which, singularly or in the aggregate, if determined adversely to

 

 

the Company or any of its subsidiaries, would reasonably be expected to have a Material
Adverse Effect or would prevent or adversely affect the ability of the Company to perform its
obligations under this Agreement; and to the best of the Company’s knowledge, no such proceedings
are threatened or contemplated by governmental authorities or threatened by others.

          (s) None of the Company or any of its subsidiaries is in (i) violation of its charter or
by-laws (or analogous governing instrument, as applicable), (ii) default in any respect, and no
event has occurred which, with notice or lapse of time or both, would constitute such a default, in
the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a
party or by which it is bound or to which any of its property or assets is subject or (iii)
violation in any respect of any law, ordinance, governmental rule, regulation or court order,
decree or judgment to which it or its property or assets may be subject except, in the case of
clauses (ii) and (iii) of this paragraph (s), for any violations or defaults which,
singularly or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

          (t) The clinical evaluations conducted by or on behalf of or sponsored by the Company or in
which the Company or its product candidates have participated that are described in the General
Disclosure Package and Prospectus or the results of which are referred to in the General Disclosure
Package or Prospectus were and, if still pending, are being conducted in all material respects in
accordance with medical and scientific research procedures that the Company reasonably believes are
appropriate. The descriptions in the General Disclosure Package and Prospectus of the results of
such clinical evaluations are accurate and fairly present the data derived from such clinical
evaluations, and the Company has no knowledge of any studies or tests performed by or on behalf of
the Company the results of which are materially inconsistent with or otherwise materially call into
question the results described or referred to in the General Disclosure Package and Prospectus.
Except to the extent disclosed in the General Disclosure Package and the Prospectus, the Company
has not received any notices or other correspondence from the United States Food and Drug
Administration (“FDA”) or any other governmental agency requiring the termination, suspension or
modification of any clinical evaluations that are described in the General Disclosure Package or
the Prospectus or the results of which are referred to in the General Disclosure Package or the
Prospectus.

          (u) None of the Company, its subsidiaries, or its or their respective business operations, is
in violation of any applicable Health Care Laws, except as would not reasonably be expected to have
a Material Adverse Effect. For purposes of this Agreement, “Health Care Laws” means (i) all federal
and state fraud and abuse laws, including, but not limited to, the federal Anti-Kickback Statute
(42 U.S.C. §1320a-7(b)), the Stark Law (42 U.S.C. §1395nn and §1395(q)), the Anti-Inducement Law
(42 U.S.C. § 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. §3729 et seq.), the
administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the exclusion laws (42 U.S.C. §
1320a-7), the civil monetary penalty laws (42 U.S.C. § 1320a-7a) and the regulations promulgated
pursuant to such statutes; (ii) the Health Insurance Portability and Accountability Act of 1996
(Pub. L. No. 104-191) and the Health Information Technology for Economic and Clinical Health Act of
2009, and the regulations promulgated thereunder and comparable state privacy and security laws,
(iii) Medicare (Title XVIII of the Social Security Act) and the regulations promulgated thereunder;
(iv) Medicaid (Title XIX of the Social Security Act) and the regulations promulgated thereunder;
(v) quality, safety and accreditation standards and requirements of all applicable state laws or
regulatory bodies; and (vi) any and all other

 

 

applicable health care laws, regulations, manual provisions, policies and administrative
guidance, each of (i) through (vi) as may be amended from time to time. The Company has not
received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any governmental authority alleging that any product, operation or
activity is in violation of any applicable Health Care Law, except as would not reasonably be
expected to have a Material Adverse Effect, and has no knowledge that any such governmental
authority is considering any such claim, litigation, arbitration, action, suit, investigation or
proceeding.

          (v) The Company and each of its subsidiaries possess all licenses, certificates,
authorizations and permits issued by, and have made all declarations and filings with, the
appropriate local, state, federal or foreign regulatory agencies or bodies which are necessary or
desirable for the ownership of their respective properties or the conduct of their respective
businesses as described in the General Disclosure Package and the Prospectus (collectively, the
“Governmental Permits”), except where any failures to possess or make the same, singularly or in
the aggregate, would not reasonably be expected to have a Material Adverse Effect. The Company and
its subsidiaries are in material compliance with all such Governmental Permits; all such
Governmental Permits are valid and in full force and effect, except where the validity or failure
to be in full force and effect would not, singularly or in the aggregate, reasonably be expected to
have a Material Adverse Effect. Neither the Company nor any subsidiary has received notification of
any revocation or modification (or proceedings related thereto) of any such Governmental Permit and
the Company has no reason to believe that any such Governmental Permit will not be renewed.

          (w) None of the Company or any of its subsidiaries is or, after giving effect to the Offering
and the application of the proceeds thereof as described in the General Disclosure Package and the
Prospectus, will be required to register as an “investment company” or an entity “controlled” by an
“investment company” within the meaning of the Investment Company Act of 1940, as amended, and the
rules and regulations of the Commission thereunder.

          (x) Neither the Company, its subsidiaries nor, to the best of the Company’s knowledge, any of
the Company’s or its subsidiaries’ officers, directors or affiliates has taken or will take,
directly or indirectly, any action designed or intended to stabilize or manipulate the price of any
security of the Company, or which caused or resulted in, or which would in the future reasonably be
expected to cause or result in, stabilization or manipulation of the price of any security of the
Company.

          (y) The Company and its subsidiaries own, possess or can timely acquire on reasonable terms
the right to use all patents, trademarks, trademark registrations, service marks, service mark
registrations, trade names, copyrights, licenses, inventions, trade secrets and rights necessary to
carry on their respective businesses as now conducted and as described in the General Disclosure
Package and the Prospectus, and the Company is not aware of any claim to the contrary or any
challenge by any other person to the rights of the Company and its subsidiaries with respect to the
foregoing. To the best of the Company’s knowledge, the Company’s business as now conducted and as
proposed to be conducted does not and will not infringe or conflict with any patents, trademarks,
service marks, trade names, copyrights, trade secrets, licenses or other intellectual property or
franchise right of any person except as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Except as described in the General Disclosure Package
and the Prospectus, no claim has been

 

 

made against the Company alleging the infringement by the Company of any patent, trademark,
service mark, trade name, copyright, trade secret, license in or other intellectual property right
or franchise right of any person, except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. The Company and each of its subsidiaries has at all
times complied in all respects with all applicable laws relating to privacy, data protection, and
the collection and use of personal information collected, used, or held for use by the Company or
its subsidiaries in the conduct of the Company’s for any of its subsidiary’s business, in each case
except as would not reasonably be expected to have a Material Adverse Effect.

          (z) The Company and each of its subsidiaries have good and marketable title in fee simple to,
or have valid rights to lease or otherwise use, all items of real or personal property that are
material to the business of the Company and its subsidiaries taken as a whole, in each case free
and clear of all liens, encumbrances, security interests, claims and defects that do not,
singularly or in the aggregate, materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company or any of its
subsidiaries; and all of the leases and subleases material to the business of the Company and its
subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries
holds properties described in the General Disclosure Package and the Prospectus, are in full force
and effect, and neither the Company nor any subsidiary has received any notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company or any
subsidiary under any of the leases or subleases mentioned above, or negatively affecting or
questioning the rights of the Company or such subsidiary to the continued possession of the leased
or subleased premises under any such lease or sublease.

          (aa) No labor disturbance by the employees of the Company or any of its subsidiaries that
would reasonably be expected to have a Material Adverse Effect either exists or, to the best of the
Company’s knowledge, is imminent. Except as set forth in the General Disclosure Package, the
Company is not aware that any key employee or significant group of employees of the Company or any
subsidiary voluntarily plans to terminate employment with the Company or any such subsidiary.

          (bb) No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income
Security Act of 1974, as amended, including the regulations and published interpretations
thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to
time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any
of the events set forth in Section 4043(b) of ERISA (other than events with respect to which the
thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or
could reasonably be expected to occur with respect to any employee benefit plan of the Company or
any of its subsidiaries which would, singularly or in the aggregate, reasonably be expected to have
a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries is
in compliance in all material respects with applicable law, including ERISA and the Code. The
Company and its subsidiaries have not incurred and would not reasonably be expected to incur
liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any
pension plan (as defined in ERISA). Each pension plan for which the Company or any of its
subsidiaries would have any liability that is intended to be qualified under Section 401(a) of the
Code is so qualified in all material respects, and nothing has occurred, whether by action or by
failure to act, which could, singularly or in the aggregate, reasonably be expected to cause the
loss of such qualification.

 

 

          (cc) The Company and its subsidiaries are in compliance with all foreign, federal, state and
local statute, law (including the common law), ordinance, rule, regulation, order, judgment, decree
or Governmental Permit, relating to the use, treatment, storage and disposal of hazardous or toxic
substances, materials or wastes and the protection of health and safety or the environment which
are applicable to their businesses (“Environmental Laws”), except where the failure to comply would
not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. There
has been no storage, generation, transportation, handling, treatment, disposal, discharge,
emission, or other release of any kind of hazardous or toxic substances, materials or wastes by,
due to, or caused by the Company or any of its subsidiaries (or, to the best of the Company’s
knowledge, any other entity for whose acts or omissions the Company or any of its subsidiaries is
or may otherwise be liable) upon any of the property now or previously owned or leased by the
Company or any of its subsidiaries, or upon any other property, in violation of, or which would
give rise to any liability under, any Environmental Law, except for any violation or liability
which would not reasonably be expected to have, singly or in the aggregate with all such violations
and liabilities, a Material Adverse Effect; and there has been no disposal, discharge, emission or
other release of any kind onto such property or into the environment surrounding such property of
any hazardous or toxic substances, materials or wastes with respect to which the Company has
knowledge, except for any such disposal, discharge, emission, or other release of any kind which
would not reasonably be expected to have, singly or in the aggregate with all such discharges and
other releases, a Material Adverse Effect.

          (dd) The Company and its subsidiaries each (i) has timely filed all necessary federal, state,
local and foreign tax returns or have properly requested extensions thereof, and all such returns
were true, complete and correct in all respects, (ii) has paid all federal, state, local and
foreign taxes, assessments, governmental or other charges due and payable for which it is liable,
including, without limitation, all sales and use taxes and all taxes which the Company or any of
its subsidiaries is obligated to withhold from amounts owing to employees, creditors and third
parties, except as may be being contested in good faith and by appropriate proceedings, and (iii)
does not have any tax deficiency or claims outstanding or assessed or, to the best of the Company’s
knowledge, proposed against any of them, except those, in each of the cases described in clauses
(i), (ii) and (iii) of this paragraph (dd), that would not, singularly or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries each has
not engaged in any transaction which is a corporate tax shelter or which could reasonably be
characterized as such by the Internal Revenue Service or any other taxing authority. The accruals
and reserves on the books and records of the Company and its subsidiaries in respect of tax
liabilities for any taxable period not yet finally determined are adequate to meet any assessments
and related liabilities for any such period, and since June 30, 2010, none of the Company or any of
its subsidiaries has incurred any liability for taxes other than in the ordinary course.

          (ee) The Company and each of its subsidiaries carry, or are covered by, insurance provided by
recognized, financially sound and reputable institutions with policies in such amounts and covering
such risks as is adequate for the conduct of their respective businesses and the value of their
respective properties and as is customary for companies engaged in similar businesses in similar
industries. The Company has no reason to believe that it or any subsidiary will not be able to (i)
renew its existing insurance coverage as and when such policies expire or (ii) obtain comparable
coverage from similar institutions as may be necessary

 

 

or appropriate to conduct its business as now conducted and at a cost that would not
reasonably be expected to have a Material Adverse Effect. The Company has not been denied any
insurance coverage that it has sought or for which it has applied.

          (ff) The Company and each of its subsidiaries maintains a system of internal control over
financial reporting (as such term is defined in Rule 13a-15 of the General Rules and Regulations
under the Exchange Act (the “Exchange Act Rules”)) that complies with the requirements of the
Exchange Act and has been designed to provide reasonable assurances that (i) transactions are
executed in accordance with management’s general or specific authorizations; (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain accountability for assets; (iii) access to assets is permitted only in accordance with
management’s general or specific authorization; and (iv) the recorded accountability for assets is
compared with existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. Since the end of the Company’s most recent audited fiscal year, there as been
(A) no material weakness in the Company’s internal control over financial reporting (whether or not
remediated) and (B) no change in the Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company’s internal control
over financial reporting. The Company maintains disclosure controls and procedures (as such is
defined in Rule 13a-15 of the Exchange Act Rules) that comply with the requirements of the Exchange
Act; such disclosure controls and procedures have been designed to ensure that information required
to be disclosed by the Company and its subsidiaries is accumulated and communicated to the
Company’s management, including the Company’s principal executive officer and principal financial
officer by others within those entities, such disclosure controls and procedures are effective in
all material respects to perform the functions for which they were established.

          (gg) The minute books of the Company and each of its subsidiaries that would be a “significant
subsidiary” within the meaning of Rule 1-02(w) of Regulation S-X under the Exchange Act have been
made available to the Agent and counsel for the Agent, and such books (i) contain a complete
summary of all meetings and actions of the board of directors (including each board committee) and
stockholders of the Company, and each of such subsidiaries since the time of its respective
incorporation or organization through the date of the latest meeting and action, and (ii)
accurately in all material respects reflect all transactions referred to in such minutes or written
consents.

          (hh) There is no franchise, lease, contract, agreement or document required by the Securities
Act or by the Rules and Regulations to be described in the General Disclosure Package and in the
Prospectus or a document incorporated by reference therein or to be filed as an exhibit to the
Registration Statement or a document incorporated by reference therein which is not described or
filed therein as required; and all descriptions of any such franchises, leases, contracts,
agreements or documents contained in the Registration Statement or the General Disclosure Package
or in any document incorporated by reference therein are accurate and complete descriptions of such
documents. Other than as described in the General Disclosure Package, no such franchise, lease,
contract or agreement has been suspended or terminated for convenience or default by the Company or
any of its subsidiaries or any of the other parties thereto, and none of the Company or any of its
subsidiaries has received notice nor does the Company have any other knowledge of any such pending
or threatened suspension or

 

 

termination, except for such pending or threatened suspensions or terminations that would not
reasonably be expected to, singularly or in the aggregate, have a Material Adverse Effect.

          (ii) No relationship, direct or indirect, exists between or among the Company and any of its
subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of
the Company or any of its subsidiaries or any of their affiliates, on the other hand, that is
required to be described in the General Disclosure Package and the Prospectus or a document
incorporated by reference therein and that is not so described.

          (jj) No person or entity has the right to require registration of shares of Common Stock or
other securities of the Company or any of its subsidiaries because of the filing or effectiveness
of the Registration Statement or otherwise, except for persons and entities who have expressly
waived such right in writing or who have been given timely and proper written notice and have
failed to exercise such right within the time or times required under the terms and conditions of
such right. Except as described in the General Disclosure Package, there are no persons with
registration rights or similar rights to have any securities registered for sale under the
Registration Statement or to include such securities in the Offering.

          (kk) None of the Company or any of its subsidiaries own any “margin securities” as that term
is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal
Reserve Board”), and none of the proceeds of the sale of the Units will be used, directly or
indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of
reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin
security or for any other purpose which might cause any of the Units to be considered a “purpose
credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

          (ll) Other than this Agreement and that certain letter agreement, dated October 26, 2010, by
and between the Company and the Agent, none of the Company or any of its subsidiaries is a party to
any contract, agreement or understanding with any person that would give rise to a valid claim
against the Company, the Agent for a brokerage commission, finder’s fee or like payment in
connection with the offering and sale of the Units or any transaction contemplated by this
Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.

          (mm) No forward-looking statement (within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act) contained in the General Disclosure Package or the Prospectus has
been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

          (nn) The Company is subject to and in compliance in all material respects with the reporting
requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is registered
pursuant to Section 12(g) of the Exchange Act and is listed on Nasdaq, and the Company has taken no
action designed to, or reasonably likely to have the effect of, terminating the registration of the
Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company
received any notification that the Commission, Nasdaq or FINRA is contemplating terminating such
registration or listing, except for the notice, dated September 16, 2009, delivered by Nasdaq to
the Company, stating that the Common Stock failed to meet the minimum bid price requirement on
Nasdaq for 30 consecutive

 

 

days. No consent, approval, authorization or order of, or filing, notification or registration
with, Nasdaq is required for the listing and trading of the shares of Common Stock on Nasdaq,
except such as will have been obtained or made, as the case may be, prior to the Closing Date.

          (oo) The Company is in material compliance with all applicable provisions of the
Sarbanes-Oxley Act of 2002 and all applicable rules and regulations promulgated thereunder or
implementing the provisions thereof (the “Sarbanes-Oxley Act”).

          (pp) The Company is in compliance with all applicable corporate governance requirements set
forth in Nasdaq Marketplace Rules.

          (qq) None of the Company, any of its subsidiaries or, to the best of the Company’s knowledge,
any director, officer, agent, employee, affiliate or other person acting on behalf of the Company
or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that has
resulted or would result in a violation of the Foreign Corrupt Practices Act of 1977, as amended,
and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of
the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an
offer, payment, promise to pay or authorization of the payment of any money, or other property,
gift, promise to give, or authorization of the giving of anything of value to any “foreign
official” (as such term is defined in the FCPA) or any foreign political party or official thereof
or any candidate for foreign political office, in contravention of the FCPA; and the Company and
its subsidiaries and, to the best of the Company’s knowledge, the Company’s affiliates have
conducted their respective businesses in compliance with the FCPA and have instituted and maintain
policies and procedures designed to ensure, and which are reasonably expected to continue to
ensure, continued compliance therewith.

          (rr) There are no transactions, arrangements or other relationships between and/or among the
Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any
unconsolidated entity, including, but not limited to, any structured finance, special purpose or
limited purpose entity that could reasonably be expected to materially affect the Company’s or any
of its subsidiaries’ liquidity or the availability of or requirements for their capital resources,
which transaction, arrangement or other relationship is required to be described in the General
Disclosure Package and the Prospectus or any document incorporated by reference therein that has
not been described as required.

          (ss) There are no outstanding loans, advances (except normal advances for business expense in
the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit
of any of the officers or directors of the Company or any of their respective family members,
except as disclosed in the General Disclosure Package and the Prospectus.

          (tt) The statistical and market related data included in the Registration Statement, the
General Disclosure Package and the Prospectus are based on or derived from sources that the Company
believes to be reliable and accurate, and such data agree with the sources from which they are
derived.

          (uu) The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the
Currency and Foreign Transactions Reporting Act of 1970, as amended,

 

 

applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Company or any of
its subsidiaries with respect to the Money Laundering Laws is pending, or to the best of the
Company’s knowledge, threatened.

          (vv) None of the Company or any of its subsidiaries nor, to the best of the Company’s
knowledge, any director, officer, agent, employee or affiliate of the Company or any of its
subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or
indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by
OFAC.

          (ww) All of the information provided to the Agent or to counsel for the Agent by the Company,
its officers and directors and the holders of any securities (debt or equity) or options to acquire
any securities of the Company in connection with letters, filings or other supplemental information
provided to FINRA pursuant to FINRA Rule 5110 or the National Association of Securities Dealers
Inc. (the “NASD”) Conduct Rule 2710 or 2720 is true, complete and correct. Neither the Company nor,
to the best of the Company’s knowledge, any of its affiliates (within the meaning of the NASD
Conduct Rule 2720(f)(1)) directly or indirectly controls, is controlled by, or is under common
control with, or is an associated person (within the meaning of Article I, Section 1(ee) of the
By-laws of FINRA) of, any member firm of FINRA. There are no affiliations with the FINRA among the
Company’s officers or directors. To the best of the Company’s knowledge, (i) no proceeds of the
Offering, excluding compensation, fees or expenses paid to the Agent, will be paid to any FINRA
member, or any person or entity associated or affiliated with a member of FINRA, and (ii) no person
or entity to whom securities of the Company have been privately issued within the 180-day period
prior to either: (a) the initial filing date of the Registration Statement or (b) the date hereof
has any relationship or affiliation or association with any member of FINRA.

          (xx) As of the date the Registration Statement was filed with the Commission and as of the
date hereof, the Company satisfied and, as of the Closing Date, the Company will satisfy, the
conditions for use of Form S-3 applicable to the Offering, set forth in the General Instructions
thereto.

          (yy) No approval of the stockholders of the Company under the rules and regulations of Nasdaq
(including Rule 5635 of the Nasdaq Marketplace Rules) is required for the Company to issue and
deliver to the Purchasers the Units.

     Any certificate signed by or on behalf of the Company and delivered to the Agent or to counsel
for the Agent shall be deemed to be a representation and warranty by the Company to the Agent and
the Purchasers as to the matters covered thereby.

     4. THE CLOSING. The time and date of closing and delivery of the documents required to be
delivered to the Agent pursuant to Sections 5 and 7 hereof shall be at 10:00 A.M.,
New York time, on March 9, 2011 (the “Closing Date”) at the office of Weintraub Genshlea Chediak,
400 Capitol Mall, Eleventh Floor, Sacramento, CA 95816, Attention: David C. Adams.

 

 

     5. FURTHER AGREEMENTS OF THE COMPANY. The Company agrees with the Agent and the Purchasers:

          (a) To prepare the Rule 462(b) Registration Statement, if necessary, in a form approved by the
Agent and file such Rule 462(b) Registration Statement with the Commission on the date hereof; to
prepare the Prospectus in a form approved by the Agent containing information previously omitted at
the time of effectiveness of the Registration Statement in reliance on rules 430A, 430B or 430C of
the Rules and Regulations and to file such Prospectus pursuant to Rule 424(b) of the Rules and
Regulations not later than the second business (2nd) day following the execution and delivery of
this Agreement or, if applicable, such earlier time as may be required by Rule 430A of the Rules
and Regulations; to notify the Agent promptly of the Company’s intention to file or prepare any
supplement or amendment to any Registration Statement or to the Prospectus and to make no amendment
or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus to
which the Agent shall reasonably object by notice to the Company after a reasonable period to
review; to advise the Agent, promptly after it receives notice thereof, of the time when any
amendment to any Registration Statement has been filed or becomes effective or any supplement to
the General Disclosure Package or the Prospectus or any amended Prospectus has been filed and to
furnish the Agent with copies thereof; to file within the time periods prescribed by the Exchange
Act, including any extension thereof, all material required to be filed by the Company with the
Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case may be;
to file promptly all reports and any definitive proxy or information statements required to be
filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the
Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a
prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations)
is required in connection with the offering or sale of the Units; to advise the Agent, promptly
after it receives notice thereof, of the issuance by the Commission of any stop order or of any
order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing
Prospectus or the Prospectus, of the suspension of the qualification of the Units for offering or
sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose,
or of any request by the Commission for the amending or supplementing of the Registration
Statement, the General Disclosure Package or the Prospectus or for additional information; and, in
the event of the issuance of any stop order or of any order preventing or suspending the use of any
Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such
qualification, and promptly to use its best efforts to obtain the withdrawal of such order.

          (b) The Company represents and agrees that, unless it obtains the prior consent of the Agent,
it has not made and will not, make any offer relating to the Units that would constitute a “free
writing prospectus” as defined in Rule 405 of the Rules and Regulations (each, a “Permitted Free
Writing Prospectus”); provided that the prior written consent of the Agent shall be deemed to have
been given in respect of the General Use Free Writing Prospectus, if any, included in Exhibit
A hereto. The Company represents that it has treated and agrees that it will treat each
Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with the
requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free
Writing Prospectus, including the requirements relating to timely filing with the Commission,
legending and record keeping and will not take any action that would result in the Agent or the
Company being required to file with the Commission pursuant

 

 

to Rule 433(d) of the Rules and Regulations a free writing prospectus prepared by or on behalf
of the Agent that the Agent otherwise would not have been required to file thereunder.

          (c) If at any time when a Prospectus relating to the Units is required to be delivered under
the Securities Act, any event occurs or condition exists as a result of which the Prospectus, as
then amended or supplemented, would include any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, or the Registration Statement, as then
amended or supplemented, would include any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein not misleading, or if for any other reason
it is necessary at any time to amend or supplement any Registration Statement or the Prospectus or
to file under the Exchange Act any document incorporated by reference in the Prospectus to comply
with the Securities Act or the Exchange Act, the Company will promptly notify the Agent, and upon
the Agent’s request, the Company will promptly prepare and file with the Commission, at the
Company’s expense, an amendment to the Registration Statement or an amendment or supplement to the
Prospectus or make an appropriate filing under Section 13 or 14 of the Exchange Act that corrects
such statement or omission or effects such compliance and will deliver to the Agent, without
charge, such number of copies thereof as the Agent may reasonably request. The Company consents to
the use of the Prospectus or any amendment or supplement thereto by the Agent.

          (d) If the General Disclosure Package is being used to solicit offers to buy the Units at a
time when the Prospectus is not yet available to prospective purchasers and any event shall occur
as a result of which, in the judgment of the Company or in the opinion of the Agent, it becomes
necessary to amend or supplement the General Disclosure Package in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or to make
the statements therein not conflict with the information contained or incorporated by reference in
the Registration Statement then on file and not superseded or modified, or if it is necessary at
any time to amend or supplement the General Disclosure Package to comply with any law, the Company
promptly will either (i) prepare, file with the Commission (if required) and furnish to the Agent
and any dealers an appropriate amendment or supplement to the General Disclosure Package or (ii)
prepare and file with the Commission an appropriate filing under the Exchange Act which shall be
incorporated by reference in the General Disclosure Package so that the General Disclosure Package
as so amended or supplemented will not, in the light of the circumstances under which they were
made, be misleading or conflict with the Registration Statement then on file, or so that the
General Disclosure Package will comply with law.

          (e) If at any time following issuance of an Issuer Free Writing Prospectus in connection with
the Offering there occurred or occurs an event or development as a result of which such Issuer Free
Writing Prospectus conflicted or will conflict with the information contained in the Registration
Statement, Pricing Prospectus or Prospectus, including any document incorporated by reference
therein and any prospectus supplement deemed to be a part thereof and not superseded or modified or
included or would include an untrue statement of a material fact or omitted or would omit to state
a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading, the Company has
promptly notified or will promptly notify the Agent so that any use of the Issuer Free Writing
Prospectus may cease until it is amended or

 

 

supplemented and has promptly amended or will promptly amend or supplement, at its own
expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue
statement or omission. The foregoing sentence does not apply to statements in or omissions from any
Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information
furnished to the Company through the Agent by or on behalf of the Agent specifically for inclusion
therein, which information the parties hereto agree is limited to the Agent’s Information (as
defined in Section 17).

          (f) To furnish promptly to the Agent and to counsel for the Agent, upon request, a signed copy
of the Registration Statement as originally filed with the Commission, and of each amendment
thereto filed with the Commission, including all consents and exhibits filed therewith.

          (g) To the extent not available on the Commission’s Electronic Data Gathering, Analysis and
Retrieval (“EDGAR”) system or any successor system, to deliver promptly to the Agent such number of
the following documents as the Agent shall reasonably request: (i) conformed copies of the
Registration Statement as originally filed with the Commission (in each case excluding exhibits),
(ii) any Preliminary Prospectus, (iii) any Issuer Free Writing Prospectus, (iv) the Prospectus (the
delivery of the documents referred to in clauses (i), (ii), (iii) and (iv) of this paragraph
(g) to be made not later than 10:00 A.M., New York time, on the business day following the
execution and delivery of this Agreement), (v) conformed copies of any amendment to the
Registration Statement (excluding exhibits), (vi) any amendment or supplement to the General
Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v) and
(vi) of this paragraph (g) to be made not later than 10:00 A.M., New York City time, on the
business day following the date of such amendment or supplement) and (vii) any document
incorporated by reference in the General Disclosure Package or the Prospectus (excluding exhibits
thereto) (the delivery of the documents referred to in clause (vi) of this paragraph (g) to
be made not later than 10:00 A.M., New York City time, on the business day following the date of
such document).

          (h) As soon as practicable, but in any event not later than 45 days after the end of the
12-month period beginning at the end of the fiscal quarter of the Company during which the most
recent effective date of the Registration Statement occurs (or 90 days after the end of such
12-month period if such 12-month period coincides with the Company’s fiscal year), the Company will
make generally available to its security holders and to the Agent an earning statement (as defined
in Rule 158(c) of the Securities Act) of the Company and its subsidiaries (which need not be
audited), covering such 12-month period which shall satisfy the provisions of Section 11(a) of the
Securities Act and the rules and regulations of the Commission thereunder.

          (i) The Company will promptly take from time to time such actions as the Agent may reasonably
request to qualify the Units for offering and sale under the securities or Blue Sky laws of such
jurisdictions (domestic or foreign) as the Agent may designate and to continue such qualifications
in effect for so long as required for the distribution of the Securities; provided that the Company
and its subsidiaries shall not be obligated to qualify as foreign corporations in any jurisdiction
in which they are not so qualified or to file a general consent to service of process in any
jurisdiction.

 

 

          (j) Upon request, during the period of five years from the date hereof, the Company will
deliver to the Agent, (i) upon request, copies of all reports or other communications furnished to
stockholders and (ii) upon request, copies of any reports and financial statements furnished or
filed with the Commission pursuant to the Exchange Act or any national securities exchange or
automatic quotation system on which the Units is listed or quoted; however, so long as the Company
is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act
and is timely filing reports with the Commission on EDGAR, it is not required to furnish such
reports or statements to the Agent.

          (k) That the Company will not, for a period of ninety (90) days from the date of this
Agreement, (the “Lock-Up Period”) without the prior written consent of the Agent, directly or
indirectly offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, any
shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common
Stock, other than (i) the Company’s sale of the Units hereunder, (ii) the issuance of restricted
Common Stock or options to acquire Common Stock pursuant to the Company’s employee benefit plans,
qualified stock option plans or other employee compensation plans as such plans are in existence on
the date hereof and described in the Prospectus, and (iii) the issuance of Common Stock pursuant to
the valid exercises of options, warrants or rights outstanding on the date hereof. The Company has
caused each executive officer and director listed in Exhibit C to furnish to the Agent,
prior to the date hereof, a letter, substantially in the form of Exhibit D hereto. The
Company also agrees that during such period, the Company will not file any registration statement,
preliminary prospectus or prospectus, or any amendment or supplement thereto, under the Securities
Act for any such transaction or which registers, or offers for sale, Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock, except for a registration
statement on Form S-8 relating to employee benefit plans. The Company hereby agrees that (i) if it
issues an earnings release or material news, or if a material event relating to the Company occurs,
during the last seventeen (17) days of the Lock-Up Period, or (ii) if prior to the expiration of
the Lock-Up Period, the Company announces that it will release earnings results during the sixteen
(16)-day period beginning on the last day of the Lock-Up Period, unless waived by the Agent in
writing, the restrictions imposed by this paragraph (k) or the letter shall continue to
apply until the expiration of the eighteen (18)-day period beginning on the issuance of the
earnings release or the occurrence of the material news or material event, as applicable, except
that such extension will not apply if, (x) the shares of Common Stock are “actively traded
securities” (as defined in Regulation M), (y) the Company meets the applicable requirements of
paragraph (a)(1) of Rule 139 under the Securities Act in the manner contemplated by FINRA’s NASD
Conduct Rule 2711(f)(4), and (z) the provisions of FINRA’s NASD Conduct Rule 2711(f)(4) do not
restrict the publishing or distribution of any research reports relating to the Company during the
15 days before or after the last day of the Lock-up Period (before giving effect to such
extension).

          (l) To supply the Agent with copies of all correspondence to and from, and all documents
issued to and by, the Commission in connection with the registration of the Units under the
Securities Act.

          (m) Prior to the Closing Date, to furnish to the Agent, promptly after they have been
prepared, copies of any unaudited interim consolidated financial statements of the Company for any
periods subsequent to the periods covered by the financial statements appearing in or incorporated
by reference into the Registration Statement and the Prospectus.

 

 

          (n) Prior to the Closing Date, not to issue any press release or other communication
directly or indirectly or hold any press conference with respect to the Company, its condition,
financial or otherwise, or earnings, business affairs or business prospects (except for routine
oral marketing communications in the ordinary course of business and consistent with the past
practices of the Company and of which the Agent is notified in advance), without the prior written
consent of the Agent, unless in the judgment of the Company and its counsel, and after notification
to the Agent, such press release or communication is required by law.

          (o) Until the Agent shall have notified the Company of the completion of the Offering, the
Company will not, and will cause its affiliated purchasers (as defined in Regulation M under the
Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any
account in which it or any of its affiliated purchasers has a beneficial interest, any Units, or
attempt to induce any person to purchase any Units; and not to, and to cause its affiliated
purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active
trading in or of raising the price of the Units.

          (p) Not to take any action prior to the Closing Date that would require the Prospectus to be
amended or supplemented pursuant to Section 5.

          (q) To at all times comply with all applicable provisions of the Sarbanes-Oxley Act in effect
from time to time.

          (r) To apply the net proceeds from the sale of the Units as set forth in the Prospectus under
the heading “Use of Proceeds.”

          (s) To use its best efforts to list, effect and maintain, subject to notice of issuance, the
Common Stock on Nasdaq.

          (t) To use its best efforts to do and perform all things required to be done or performed
under this Agreement by the Company prior to the Closing Date and to satisfy all conditions
precedent to the delivery of the Units.

     6. PAYMENT OF FEES, COSTS AND EXPENSES. The Company agrees to pay, or reimburse if paid by the
Agent, whether or not the transactions contemplated hereby are consummated or this Agreement is
prevented from becoming effective or is terminated: (a) the costs incident to the authorization,
issuance, sale, preparation and delivery of the Units to the Purchasers and any taxes payable in
that connection; (b) the costs incident to the registration of the Units, the Shares, the Warrants
and the Warrant Shares under the Securities Act; (c) the costs incident to the preparation,
printing and distribution of the Registration Statement, the Base Prospectus, any Preliminary
Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any
amendments, supplements and exhibits thereto or any document incorporated by reference therein and
the costs of printing, reproducing and distributing any transaction document by mail, telex or
other means of communications; (d) the fees and expenses (including related fees and expenses of
counsel for the Agent) incurred in connection with securing any required review by FINRA of the
terms of the sale of the Units and any filings made with FINRA; (e) any applicable listing,
quotation or other fees and expenses; (f) the fees and expenses (including related fees and
expenses of counsel to the Agent) of qualifying the Units under the securities laws of the several
jurisdictions as provided in Section 5(i) and of preparing, printing and distributing
wrappers, Blue Sky Memoranda and

 

 

Legal Investment Surveys (if any); (g) the cost of preparing and printing stock certificates;
(h) all fees and expenses of the registrar and transfer agent of the Units, and (i) and all other
fees, costs and expenses incurred by the Company incident to the Offering by, or the performance of
the obligations of, the Company under this Agreement (including, without limitation, the fees,
costs and expenses of the Company’s counsel and the Company’s independent accountants and the
travel and other expenses actually incurred by Company’s personnel in connection with any “road
show” including, without limitation, any expenses advanced by the Agent on the Company’s behalf
(which will be promptly reimbursed)). Except to the extent otherwise provided in this Section 6 and
in Section 10, the Agent shall pay its own costs and expenses, including the fees and expenses of
its counsel and the expenses of advertising any offering of the Shares and the Warrants made by the
Agent.

     7. CONDITIONS TO THE OBLIGATIONS OF THE AGENT AND THE PURCHASERS, AND THE SALE OF THE UNITS.
The obligations of the Agent hereunder and the Purchasers under the Subscription Agreements, and
the Closing of the sale of the Units, are subject to the accuracy, when made and as of the
Applicable Time and on the Closing Date, of the representations and warranties of the Company
contained herein, to the accuracy of the statements of the Company made in any certificates
pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder,
and to each of the following additional terms and conditions:

          (a) The Registration Statement is effective under the Securities Act, and no stop order
suspending the effectiveness of the Registration Statement or any part thereof, preventing or
suspending the use of any Base Prospectus, any Preliminary Prospectus, the Prospectus or any
Permitted Free Writing Prospectus or any part thereof shall have been issued and no proceedings for
that purpose or pursuant to Section 8A under the Securities Act shall have been initiated or
threatened by the Commission, and all requests for additional information on the part of the
Commission (to be included or incorporated by reference in the Registration Statement or the
Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Agent;
the Rule 462(b) Registration Statement, if any, any Issuer Free Writing Prospectus, and the
Prospectus shall have been filed with the Commission within the applicable time period prescribed
for such filing by, and in compliance with, the Rules and Regulations and in accordance with
Section 5(a), and the Rule 462(b) Registration Statement, if any, shall have become
effective immediately upon its filing with the Commission; and, if applicable, FINRA shall have
raised no objection to the fairness and reasonableness of the terms of this Agreement or the
transactions contemplated hereby.

          (b) The Agent shall not have discovered and disclosed to the Company on or prior to the
Closing Date that the Registration Statement or any amendment or supplement thereto contains an
untrue statement of a fact that, in the opinion of the Agent, is material or omits to state any
fact which, in the opinion of the Agent, is material and is required to be stated therein or is
necessary to make the statements therein not misleading, or that the General Disclosure Package,
any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto
contains an untrue statement of fact that, in the opinion of the Agent, is material or omits to
state any fact that, in the opinion of the Agent, is material and is necessary in order to make the
statements, in the light of the circumstances in which they were made, not misleading.

 

 

          (c) All corporate proceedings and other legal matters incident to the authorization, form and
validity of each of this Agreement, the Subscription Agreements, the Warrants, the Units, the
Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus, if
any, and the Prospectus and all other legal matters relating to this Agreement and the transactions
contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the
Agent, and the Company shall have furnished to such counsel all documents and information that they
may reasonably request to enable them to pass upon such matters.

          (d) Weintraub Genshlea Chediak shall have furnished to the Agent, such counsel’s written
opinion and negative assurances letter, as counsel to the Company, each addressed to the Agent and
dated the Closing Date, in the form and substance reasonably satisfactory to the Agent.

          (e) The Agent shall have received from Paul, Hastings, Janofsky & Walker LLP, counsel for the
Agent, such opinion or opinions, addressed to the Agent dated the Closing Date, with respect to
such matters as the Agent may reasonably require, and the Company shall have furnished to such
counsel such documents as they reasonably request for enabling them to pass upon such matters.

          (f) At the time of the execution of this Agreement, the Agent shall have received from Ernst &
Young LLP, a letter, addressed to the Agent, executed and dated such date, in form and substance
satisfactory to the Agent, (i) confirming that they are an independent registered accounting firm
with respect to the Company and its subsidiaries within the meaning of the Securities Act and the
Rules and Regulations and the PCAOB and (ii) stating the conclusions and findings of such firm, of
the type ordinarily included in accountants’ “comfort letters” to underwriters, with respect to the
financial statements and certain financial information contained or incorporated by reference in
the Registration Statement, the General Disclosure Package and the Prospectus.

          (g) On the effective date of any post-effective amendment to any Registration Statement and on
the Closing Date, the Agent shall have received a letter (the “Bring-Down Letter”) from Ernst &
Young LLP addressed to the Agent and dated the effective date of such post-effective amendment or
the Closing Date, as the case may be, confirming, as of the date of the Bring-Down Letter (or, with
respect to matters involving changes or developments since the respective dates as of which
specified financial information is given in the General Disclosure Package and the Prospectus, as
the case may be, as of a date not more than three (3) business days prior to the date of the
Bring-Down Letter), the conclusions and findings of such firm, of the type ordinarily included in
accountants’ “comfort letters” to underwriters, with respect to the financial information and other
matters covered by its letter delivered to the Agent concurrently with the execution of this
Agreement pursuant to paragraph (f) of this Section 7.

          (h) The Company shall have furnished to the Agent a certificate, dated the Closing Date, of
its Chief Executive Officer and its Chief Financial Officer stating in their capacities as officers
of the Company that (i) such officers have carefully examined the Registration Statement, the
General Disclosure Package, any Permitted Free Writing Prospectus and the Prospectus and, in their
opinion, the Registration Statement and each amendment thereto, at the Applicable Time and as of
the date of this Agreement and as of the Closing Date did not

 

 

include any untrue statement of a material fact and did not omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading, and the
General Disclosure Package, as of the Applicable Time and as of the Closing Date, any Permitted
Free Writing Prospectus as of its date and as of the Closing Date, the Prospectus and each
amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did
not include any untrue statement of a material fact and did not omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances in which they
were made, not misleading, (ii) since the effective date of the initial Registration Statement, no
event has occurred that should have been set forth in a supplement or amendment to the Registration
Statement, the General Disclosure Package or the Prospectus that was not so set forth therein,
(iii) to the best of their knowledge, as of the Closing Date, the representations and warranties of
the Company in this Agreement are true and correct in all material respects, (except that any such
representation and warranty shall be true and correct in all respects where such representation and
warranty is qualified with respect to materiality), and the Company has complied with all
agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or
prior to the Closing Date, and (iv) there has not been, subsequent to the date of the most recent
audited financial statements included or incorporated by reference in the General Disclosure
Package, any material adverse change in the financial position or results of operations of the
Company and its subsidiaries taken as a whole, or any change or development that, singularly or in
the aggregate, would reasonably be expected to involve a material adverse change or a prospective
material adverse change, in or affecting the condition (financial or otherwise), results of
operations, business, liquidity, assets or prospects of the Company and its subsidiaries taken as a
whole, except as set forth in the Prospectus.

          (i) Since the date of the latest audited financial statements included in the General
Disclosure Package or incorporated by reference in the General Disclosure Package as of the date
hereof, (i) none of the Company or any of its subsidiaries shall have sustained any loss or
interference with its business from fire, explosion, flood or other calamity, whether or not
covered by insurance, or from any labor dispute or court or governmental action, order or decree,
and (ii) there shall not have been any change in the capital stock (other than issuance of options
in the ordinary course of business and pursuant to the Company’s stock option plans described in
the General Disclosure Package and the Prospectus or Common Stock issued pursuant to the exercise
of warrants or upon the exercise of stock options previously outstanding under the Company’s stock
option plans and the issuance of Common Stock pursuant to employee stock purchase plans) or
long-term debt of the Company nor any of its subsidiaries, or any change, or any development
involving a prospective change, in or affecting the business, general affairs, management,
financial position, liquidity, stockholders’ equity or results of operations of the Company and its
subsidiaries, otherwise than as set forth in the General Disclosure Package in each of the above
instances, the effect of which, in any such case described in clause (i) or (ii) of this
paragraph (i), is, in the judgment of the Agent, so material and adverse as to make it
impracticable or inadvisable to proceed with the sale or delivery of the Units on the terms and in
the manner contemplated in the General Disclosure Package.

          (j) No action shall have been taken and no law, statute, rule, regulation or order shall have
been enacted, adopted or issued by any governmental agency or body which would prevent the issuance
or sale of the Units or materially and adversely affect or potentially materially and adversely
affect the business or operations of the Company and its subsidiaries, taken as a whole; and no
injunction, restraining order or order of any other nature by any federal

 

 

or state court of competent jurisdiction shall have been issued which would prevent the
issuance or sale of the Units or materially and adversely affect or potentially materially and
adversely affect the business or operations of the Company and its subsidiaries, taken as a whole.

          (k) Subsequent to the execution and delivery of this Agreement there shall not have occurred
any of the following: (i) trading in securities generally on the New York Stock Exchange, Nasdaq or
the NYSE Amex LLC or in the over-the-counter market, or trading in any securities of the Company on
any exchange or in the over-the-counter market, shall have been suspended or materially limited, or
minimum or maximum prices or maximum range for prices shall have been established on any such
exchange or such market by the Commission, by such exchange or market or by any other regulatory
body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been
declared by Federal or state authorities or a material disruption has occurred in commercial
banking or securities settlement or clearance services in the United States, (iii) the United
States shall have become engaged in hostilities, or the subject of an act of terrorism, or there
shall have been an outbreak of or escalation in hostilities involving the United States, or there
shall have been a declaration of a national emergency or war by the United States or (iv) there
shall have occurred such a material adverse change in general economic, political or financial
conditions (or the effect of international conditions on the financial markets in the United States
shall be such) as to make it, in the judgment of the Agent, impracticable or inadvisable to proceed
with the sale or delivery of the Units on the terms and in the manner contemplated in the General
Disclosure Package and the Prospectus.

          (l) The Company shall have filed an Application for Listing of Additional Shares covering the
Shares and the Warrant Shares with Nasdaq and Nasdaq shall not have rejected such Application.

          (m) The Agent shall have received the written agreements, substantially in the form of
Exhibit D hereto, of the executive officers and directors of the Company listed in
Exhibit C to this Agreement, and each such agreement shall be in full force and effect.

          (n) The Company shall have entered into Subscription Agreements with each of the Purchasers
and such agreements shall be in full force and effect.

          (o) The Company shall have prepared and filed with the Commission a Current Report on Form 8-K
with respect to the Offering, which shall include as an exhibit thereto this Agreement, the form of
Subscription Agreement and the form of Warrant.

          (p) On or prior to the Closing Date, the Company shall have furnished to the Agent such
further information, opinions, certificates, letters or documents as the Agent shall have
reasonably requested.

     All opinions, letters, evidence and certificates mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Agent.

 

 

     8. INDEMNIFICATION AND CONTRIBUTION.

          (a) The Company shall indemnify and hold harmless the Agent, each of its affiliates and each
of its and their respective directors, officers, members, employees, representatives and agents,
and each person, if any, who controls any Agent within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (collectively the “Agent Indemnified Parties,” and each a
“Agent Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any
action, investigation or proceeding in respect thereof), joint or several, to which a Agent
Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss,
claim, damage, expense, liability, action, investigation or proceeding arises out of or is based
upon (A) any untrue statement or alleged untrue statement of a material fact contained in any
Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or
required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration
Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by
reference therein, (B) the omission or alleged omission to state in any Preliminary Prospectus, any
Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to
Rule 433(d) of the Rules and Regulations, any Registration Statement or the Prospectus, or in any
amendment or supplement thereto or document incorporated by reference therein, a material fact
required to be stated therein or necessary to make the statements therein in the light of (other
than in the case of any Registration Statement) the circumstances under which they are made not
misleading, or (C) any breach of the representations and warranties of the Company contained herein
or the failure of the Company to perform its obligations hereunder or pursuant to any law, any act
or failure to act, or any alleged act or failure to act, by the Agent in connection with, or
relating in any manner to, the Units or the Offering, and which is included as part of or referred
to in any loss, claim, damage, expense, liability, action, investigation or proceeding arising out
of or based upon matters covered by subclause (A), (B) or (C) above of this Section 8(a)
(provided that the Company shall not be liable in the case of any matter covered by this subclause
(C) to the extent that it is determined in a final judgment by a court of competent jurisdiction
that such loss, claim, damage, expense or liability resulted solely and directly from any such act,
or failure to act, undertaken or omitted to be taken by the Agent through its gross negligence or
willful misconduct), and shall reimburse each Agent Indemnified Party promptly upon demand for any
legal fees or other expenses reasonably incurred by that Agent Indemnified Party in connection with
investigating, or preparing to defend, or defending against, or appearing as a third party witness
in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense,
liability, action, investigation or proceeding, as such fees and expenses are incurred; provided,
however, that the Company shall not be liable in any such case to the extent that any such loss,
claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged
untrue statement in, or omission or alleged omission from any Preliminary Prospectus, any
Registration Statement or the Prospectus, or any such amendment or supplement thereto, or any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information
furnished to the Company through the Agent by or on behalf of the Agent specifically for use
therein, which information the parties hereto agree is limited to the Agent’s Information (as
defined in Section 17). The indemnity agreement in this Section 8(a) is not
exclusive and is and will be in addition to any liability, which the Company might otherwise have
and shall not limit any rights or remedies which may otherwise be available at law or in equity to
each Agent Indemnified Party.

 

 

          (b) The Agent shall indemnify and hold harmless the Company and its directors, its officers
who signed the Registration Statement and each person, if any, who controls the Company within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the
“Company Indemnified Parties” and each a “Company Indemnified Party”) against any loss, claim,
damage, expense or liability whatsoever (or any action, investigation or proceeding in respect
thereof), joint or several, to which such Company Indemnified Party may become subject, under the
Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action,
investigation or proceeding arises out of or is based upon (i) any untrue statement or alleged
untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free
Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d)
of the Rules and Regulations, any Registration Statement or the Prospectus, or in any amendment or
supplement thereto, or (ii) the omission or alleged omission to state in any Preliminary
Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be
filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration Statement or the
Prospectus, or in any amendment or supplement thereto, a material fact required to be stated
therein or necessary to make the statements therein in the light of (other than in the case of any
Registration Statement) the circumstances under which they are made not misleading, but in each
case only to the extent that the untrue statement or alleged untrue statement or omission or
alleged omission was made in reliance upon and in conformity with written information furnished to
the Company through the Agent by or on behalf of the Agent specifically for use therein, which
information the parties hereto agree is limited to the Agent’s Information (as defined in
Section 17), and shall reimburse the Company Indemnified Parties for any legal or other
expenses reasonably incurred by such party in connection with investigating or preparing to defend
or defending against or appearing as third party witness in connection with any such loss, claim,
damage, liability, action, investigation or proceeding, as such fees and expenses are incurred.
Notwithstanding the provisions of this Section 8(b), in no event shall any indemnity by the
Agent under this Section 8(b) exceed the total compensation received by the Agent in
accordance with Section 2.5. This indemnity agreement is not exclusive and will be in
addition to any liability which the Agent might otherwise have and shall not limit any rights or
remedies which may otherwise be available under this Agreement, at law or in equity to the Company
Indemnified Parties.

          (c) Promptly after receipt by an indemnified party under this Section 8 of notice of
the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be
made against an indemnifying party under this Section 8, notify such indemnifying party in
writing of the commencement of that action; provided, however, that the failure to notify the
indemnifying party shall not relieve it from any liability which it may have under this Section
8 except to the extent it has been materially prejudiced by such failure; and, provided,
further, that the failure to notify an indemnifying party shall not relieve it from any liability
which it may have to an indemnified party otherwise than under this Section 8. If any such
action shall be brought against an indemnified party, and it shall notify the indemnifying party
thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it
wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such
action with counsel reasonably satisfactory to the indemnified party (which counsel shall not,
except with the written consent of the indemnified party, be counsel to the indemnifying party).
After notice from the indemnifying party to the indemnified party of its election to assume the
defense of such action, except as provided herein, the indemnifying party shall not be liable to
the indemnified party under Section 8 for any legal or other expenses subsequently

 

 

incurred by the indemnified party in connection with the defense of such action other than
reasonable costs of investigation; provided, however, that any indemnified party shall have the
right to employ separate counsel in any such action and to participate in the defense of such
action but the fees and expenses of such counsel (other than reasonable costs of investigation)
shall be at the expense of such indemnified party unless (i) the employment thereof has been
specifically authorized in writing by the Company in the case of a claim for indemnification under
Section 8(a) or Section 2.6 or the Agent in the case of a claim for indemnification
under Section 8(b), (ii) such indemnified party shall have been advised by its counsel that
there may be one or more legal defenses available to it which are different from or additional to
those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the
defense of such action and employ counsel reasonably satisfactory to the indemnified party within a
reasonable period of time after notice of the commencement of the action or the indemnifying party
does not diligently defend the action after assumption of the defense, in which case, if such
indemnified party notifies the indemnifying party in writing that it elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall not have the right
to assume the defense of (or, in the case of a failure to diligently defend the action after
assumption of the defense, to continue to defend) such action on behalf of such indemnified party
and the indemnifying party shall be responsible for legal or other expenses subsequently incurred
by such indemnified party in connection with the defense of such action; provided, however, that
the indemnifying party shall not, in connection with any one such action or separate but
substantially similar or related actions in the same jurisdiction arising out of the same general
allegations or circumstances, be liable for the reasonable fees and expenses of more than one
separate firm of attorneys at any time for all such indemnified parties (in addition to any local
counsel), which firm shall be designated in writing by the Agent if the indemnified parties under
this Section 8 consist of the Agent Indemnified Party or by the Company if the indemnified
parties under this Section 8 consist of any Company Indemnified Parties. Subject to this
Section 8(c), the amount payable by an indemnifying party under Section 8 shall
include, but not be limited to, (x) reasonable legal fees and expenses of counsel to the
indemnified party and any other expenses in investigating, or preparing to defend or defending
against, or appearing as a third party witness in respect of, or otherwise incurred in connection
with, any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any
of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of judgment with respect to any pending or
threatened action or any claim whatsoever, in respect of which indemnification or contribution
could be sought under this Section 8 (whether or not the indemnified parties are actual or
potential parties thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party in form and substance reasonably satisfactory to
such indemnified party from all liability arising out of such action or claim and (ii) does not
include a statement as to or an admission of fault, culpability or a failure to act by or on behalf
of any indemnified party. Subject to the provisions of the following sentence, no indemnifying
party shall be liable for settlement of any pending or threatened action or any claim whatsoever
that is effected without its written consent (which consent shall not be unreasonably withheld or
delayed), but if settled with its written consent, if its consent has been unreasonably withheld or
delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party
agrees to indemnify and hold harmless any indemnified party from and against any loss or liability
by reason of such settlement or judgment. In addition, if at any time an indemnified party shall
have requested that an indemnifying party reimburse the indemnified party for reasonable fees and
expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of
the nature

 

 

contemplated herein effected without its written consent if (i) such settlement is entered into
more than forty-five (45) days after receipt by such indemnifying party of the request for
reimbursement, (ii) such indemnifying party shall have received notice of the terms of such
settlement at least thirty (30) days prior to such settlement being entered into and (iii) such
indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement.

          (d) If the indemnification provided for in this Section 8 is unavailable or
insufficient to hold harmless an indemnified party under Section 8(a) or Section
8(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party,
contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result
of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in
respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the
relative benefits received by the Company on the one hand and the Agent on the other hand from the
Offering, or (ii) if the allocation provided by clause (i) of this Section 8(d) is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i) of this Section 8(d) but also the relative fault of the
Company on the one hand and the Agent on the other with respect to the statements, omissions, acts
or failures to act which resulted in such loss, claim, damage, expense or liability (or any action,
investigation or proceeding in respect thereof) as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Agent on the
other with respect to such offering shall be deemed to be in the same proportion as the total net
proceeds from the Offering (before deducting expenses) received by the Company bear to the total
Placement Fee received by the Agent in connection with the Offering, in each case as set forth in
the table on the cover page of the Prospectus. The relative fault of the Company on the one hand
and the Agent on the other shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company on the one hand or the Agent on the
other, the intent of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided
that the parties hereto agree that the written information furnished to the Company by the Agent by
and on behalf of the Agent for use in any Preliminary Prospectus, any Registration Statement or the
Prospectus, or in any amendment or supplement thereto, consists solely of the Agent’s Information
as defined in Section 17. The Company and the Agent agree that it would not be just and
equitable if contributions pursuant to this Section 8(d) were to be determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable
considerations referred to herein. The amount paid or payable by an indemnified party as a result
of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to
above in this Section 8(d) shall be deemed to include, for purposes of this Section
8(d), any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating, preparing to defend or defending against or appearing as a third party witness
in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense,
liability, action, investigation or proceeding. Notwithstanding the provisions of this Section
8(d), the Agent shall not be required to contribute any amount in excess of the total
compensation received by the Agent in accordance with Section 2.5 less the amount of any
damages which the Agent has otherwise paid or become liable to pay by reason of any untrue or
alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or
alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the

 

 

Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

     9. TERMINATION. The obligations of the Agent and the Purchasers hereunder and under the
Subscription Agreements may be terminated by the Agent, in its sole and absolute discretion, by
notice given to the Company prior to delivery of and payment for the Units if, prior to that time,
any of the events described in Section 7(i), Section 7(j) or Section 7(k)
have occurred or if the Purchasers shall decline to purchase the Units for any reason permitted
under this Agreement or the Subscription Agreements.

     10. REIMBURSEMENT OF PLACEMENT AGENT’S EXPENSES. Notwithstanding anything to the contrary in
this Agreement, if (a) this Agreement shall have been terminated pursuant to Section 9, (b)
the Company shall fail to tender the Units for delivery to the Purchasers for any reason not
permitted under this Agreement, (c) the Purchasers shall decline to purchase the Units for any
reason permitted under this Agreement or (d) the sale of the Units is not consummated because any
condition to the obligations of the Purchasers or the Agent set forth herein is not satisfied or
because of the refusal, inability or failure on the part of the Company to perform any agreement
herein or to satisfy any condition or to comply with the provisions hereof, then in addition to the
payment of amounts in accordance with Section 6, the Company shall reimburse the Agent for
the reasonable out-of-pocket accountable fees, costs and expenses of the Agent’s counsel and for
such other reasonable accountable out-of-pocket expenses as shall have been incurred by them in
connection with this Agreement and the proposed purchase of the Units, and upon demand, the Company
shall pay the full amount thereof to the Agent.

     11. ABSENCE OF FIDUCIARY RELATIONSHIP. The Company acknowledges and agrees that:

          (a) The Agent’s responsibility to the Company is solely contractual in nature, the Agent has
been retained solely to act as a placement agent in connection with the Offering and no fiduciary,
advisory or agency relationship between the Company, on the one hand, and the Agent, on the other
hand, has been created in respect of any of the transactions contemplated by this Agreement,
irrespective of whether the Agent has advised or is advising the Company on other matters;

          (b) the price of the Units set forth in this Agreement was established by the Company
following discussions and arms-length negotiations with the Agent, and the Company is capable of
evaluating and understanding, and understands and accepts, the terms, risks and conditions of the
transactions contemplated by this Agreement;

          (c) it has been advised that the Agent and its affiliates are engaged in a broad range of
transactions which may involve interests that differ from those of the Company and that the Agent
has no obligation to disclose such interests and transactions to the Company by virtue of any
fiduciary, advisory or agency relationship; and

          (d) it waives, to the fullest extent permitted by law, any claims it may have against the
Agent for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that the Agent
shall have no liability (whether direct or indirect) to the Company in respect of such a

 

 

fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of
the Company, including stockholders, employees or creditors of the Company.

     12. SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall inure to the
benefit of and be binding upon the Agent, the Company, and their respective successors and assigns.
This Agreement shall also inure to the benefit of the Purchasers and each of their respective
successors and assigns, which shall be third party beneficiaries hereof. As provided in the
Subscription Agreements, the determination as to whether any condition in Section 7 hereof
shall have been satisfied, and the waiver of any condition in Section 7 hereof, may be made
by the Agent in its sole discretion, and any such determination or waiver shall be binding on each
of the Purchasers and shall not require the consent of any Purchaser. Nothing expressed or
mentioned in this Agreement is intended or shall be construed to give any person, other than the
persons mentioned in the preceding sentences, any legal or equitable right, remedy or claim under
or in respect of this Agreement, or any provisions herein contained, this Agreement and all
conditions and provisions hereof being intended to be and being for the sole and exclusive benefit
of such persons and for the benefit of no other person; except that the representations,
warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall
also be for the benefit of the Agent Indemnified Parties and the indemnities of the Agent shall be
for the benefit of the Company Indemnified Parties. It is understood that the Agent’s
responsibility to the Company is solely contractual in nature and that the Agent does not owe the
Company, or any other party, any fiduciary duty as a result of this Agreement. No Purchaser shall
be deemed to be a successor or assign by reason merely of such purchase.

     13. SURVIVAL OF INDEMNITIES, REPRESENTATIONS, WARRANTIES, ETC. The respective indemnities,
covenants, agreements, representations, warranties and other statements of the Company and the
Agent, as set forth in this Agreement or made by them respectively, pursuant to this Agreement,
shall remain in full force and effect, regardless of any investigation made by or on behalf of the
Agent, the Company, the Purchasers or any person controlling any of them and shall survive delivery
of and payment for the Units; provided, however, that notwithstanding the foregoing, with respect
to the Purchasers, such survivability shall be limited as set forth in the Subscription Agreements.
Notwithstanding any termination of this Agreement, including without limitation any termination
pursuant to Sections 9 or 10, the indemnity and contribution agreements contained
in Section 8 and the covenants, representations, warranties set forth in this Agreement
shall not terminate and shall remain in full force and effect at all times.

     14. NOTICES. All statements, requests, notices and agreements hereunder shall be in writing,
and:

          (a) if to the Agent, shall be delivered or sent by mail, telex, facsimile transmission,
overnight courier or email to Houlihan Lokey Capital, Inc., One Sansome Street, Suite 1700, San
Francisco, CA 94104, Attention: John Soden, Fax: (415) 974-5969; Email: jsoden@hl.com; with a copy
to Paul, Hastings, Janofsky & Walker LLP, 55 Second Street, Twenty-Fourth Floor, San Francisco, CA
94105, Attention: Jeffrey T. Hartlin, Fax: (415) 856-7124; Email: jeffhartlin@paulhastings.com;

          (b) if to the Company, shall be delivered or sent by mail, telex, facsimile transmission,
overnight courier or email to ThermoGenesis Corp., 2711 Citrus Road, Rancho

 

 

Cordova, California 95742, Attention: Matthew T. Plavan, CFO & EVP, Business Development, Fax:
(916) 858-5197; with a copy to Weintraub Genshlea Chediak, 400 Capitol Mall, Eleventh Floor,
Sacramento, CA 95816, Attention: David C. Adams, Fax: (916) 446-1611; Email: dadams@weintraub.com.

          Any such statements, requests, notices or agreements shall take effect at the time of receipt
thereof, except that any such statement, request, notice or agreement delivered or sent by email
shall take effect at the time of confirmation of receipt thereof by the recipient thereof.

     15. DEFINITION OF CERTAIN TERMS. For purposes of this Agreement, (a) “business day” means any
day on which the New York Stock Exchange, Inc. is open for trading, (b) “knowledge” means the
knowledge of the officers of the Company after reasonable inquiry and (c) “subsidiary” has the
meaning set forth in Rule 405 of the Rules and Regulations.

     16. GOVERNING LAW, AGENT FOR SERVICE AND JURISDICTION. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, INCLUDING WITHOUT LIMITATION
SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW. NO LEGAL PROCEEDING MAY BE COMMENCED,
PROSECUTED OR CONTINUED IN ANY COURT OTHER THAN THE COURTS OF THE STATE OF NEW YORK LOCATED IN THE
CITY AND COUNTY OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW
YORK, WHICH COURTS SHALL HAVE JURISDICTION OVER THE ADJUDICATION OF SUCH MATTERS, AND THE COMPANY
AND THE AGENT EACH HEREBY CONSENT TO THE JURISDICTION OF SUCH COURTS AND PERSONAL SERVICE WITH
RESPECT THERETO. THE COMPANY AND THE AGENT EACH HEREBY CONSENT TO PERSONAL JURISDICTION, SERVICE
AND VENUE IN ANY COURT IN WHICH ANY LEGAL PROCEEDING ARISING OUT OF OR IN ANY WAY RELATING TO THIS
AGREEMENT IS BROUGHT BY ANY THIRD PARTY AGAINST THE COMPANY OR THE AGENT. THE COMPANY AND THE AGENT
EACH HEREBY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED UPON CONTRACT,
TORT OR OTHERWISE) IN ANY WAY ARISING OUT OF OR RELATING TO THIS AGREEMENT. THE COMPANY AGREES THAT
A FINAL JUDGMENT IN ANY SUCH LEGAL PROCEEDING BROUGHT IN ANY SUCH COURT SHALL BE CONCLUSIVE AND
BINDING UPON THE COMPANY AND THE AGENT AND MAY BE ENFORCED IN ANY OTHER COURTS IN THE JURISDICTION
OF WHICH THE COMPANY IS OR MAY BE SUBJECT, BY SUIT UPON SUCH JUDGMENT.

     17. PLACEMENT AGENT’S INFORMATION. The parties hereto acknowledge and agree that, for all
purposes of this Agreement, the Agent’s Information consists solely of the following information in
the Prospectus: (i) the last paragraph on the front cover page concerning the terms of the offering
by the Agent; and (ii) the statements concerning the Agent contained in the sixth paragraph under
the heading “Plan of Distribution” in the Prospectus Supplement.

     18. PARTIAL UNENFORCEABILITY. The invalidity or unenforceability of any section, paragraph,
clause or provision of this Agreement shall not affect the validity or enforceability of any other
section, paragraph, clause or provision hereof. If any section,

 

 

paragraph, clause or provision of this Agreement is for any reason determined to be invalid or
unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as
are necessary to make it valid and enforceable.

     19. GENERAL. This Agreement constitutes the entire agreement of the parties to this Agreement
and supersedes all prior written or oral and all contemporaneous oral agreements, understandings
and negotiations with respect to the subject matter hereof. In this Agreement, the masculine,
feminine and neuter genders and the singular and the plural include one another. The section
headings in this Agreement are for the convenience of the parties only and will not affect the
construction or interpretation of this Agreement. This Agreement may be amended or modified, and
the observance of any term of this Agreement may be waived, only by a writing signed by the Company
and the Agent.

     20. COUNTERPARTS. This Agreement may be signed in any number of counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument and such signatures may be delivered by facsimile or by e-mail delivery of a “.pdf”
format data file.

 

 

     If the foregoing is in accordance with your understanding of the agreement between the Company
and the Agent, kindly indicate your acceptance in the space provided for that purpose below.

	 	 	 	 	 
	 	Very truly yours,

THERMOGENESIS CORP.

 	 
	 	By:  	/s/ J. Melville Engle
 	 
	 	 	Name:  	J. Melville Engle 	 
	 	 	Title:  	Chief Executive Officer & Chairman 	 
	 

[Signature Page to Thermogenesis Corp. Placement Agent Agreement]

 

 

Accepted as of the date

first above written:

HOULIHAN LOKEY CAPITAL, INC.

	 	 	 	 	 
	By:  	                       /s/ John V. Soden
 	 	 
	 	Name:  	John V. Soden 	 	 
	 	Title:  	Managing Director 	 	 

[Signature Page to Thermogenesis Corp. Placement Agent Agreement]

 

 

EXHIBIT A

Form of Subscription Agreement

     See Exhibit 10.2 filed herein.

 

 

EXHIBIT B

General Use Free Writing Prospectuses

     None

 

 

EXHIBIT C

List of officers and directors subject to Section 5

Directors

Hubert E. Huckel, M.D.

David W. Carter

Patrick J. McEnany

Craig W. Moore

Mahendra S. Rao, Ph.D., M.D.

J. Melville Engle

Section 16 Officers

Matthew T. Plavan

Jorge Artiles

Hal Baker

Moni Shavit

 

 

Exhibit D

Form of Lock Up Agreement

January ____, 2011

HOULIHAN LOKEY CAPITAL, INC.

One Sansome Street, Suite 1700

San Francisco, CA 94104

	 	Re: 	 	 ThermoGenesis Corp. — Registered Offering of Common Stock

Dear Sirs:

     This Agreement is being delivered to you in connection with the proposed Placement Agent
Agreement (the “Placement Agent Agreement”) among ThermoGenesis Corp., a Delaware corporation (the
“Company”) and Houlihan Lokey Capital, Inc. (“Houlihan” or the “Representative”), relating to the
proposed offering of shares of the common stock, par value $0.001 per share (the “Common Stock”),
of the Company.

     In order to induce you to enter into the Placement Agent Agreement, and in light of the
benefits that the offering of the Common Stock will confer upon the undersigned in his or her
capacity as a security holder and/or an officer, director or employee of the Company, and for good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
undersigned agrees with the Representative that, during the period beginning on and including the
date of the Placement Agent Agreement through and including the date that is the 90th day after the
date of the Placement Agent Agreement (the “Lock-Up Period”), the undersigned will not, without the
prior written consent of Houlihan, directly or indirectly, (i) offer, sell, assign, transfer,
pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose
of, any Common Stock (including, without limitation, Common Stock which may be deemed to be
beneficially owned by the undersigned in accordance with the rules and regulations promulgated
under the Securities Act of 1933, as the same may be amended or supplemented from time to time
(such shares, the “Beneficially Owned Shares”)) or securities convertible into or exercisable or
exchangeable for Common Stock; (ii) enter into any swap, hedge or similar agreement or arrangement
that transfers in whole or in part, the economic risk of ownership of the Beneficially Owned Shares
or securities convertible into or exercisable or exchangeable for Common Stock, whether now owned
or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter
acquires the power of disposition, or (iii) engage in any short selling of the Common Stock or
securities convertible into or exercisable or exchangeable for Common Stock. To the extent you are
at such time providing research coverage to the Company and subject to the restrictions set forth
in FINRA Rule 2711(f)(4), then if (i) the Company issues an earnings release or material news or a
material event relating to the Company occurs during the last 17 days of the Lock-Up Period, or
(ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release
earnings results during the 16-day period beginning on the last day of the Lock-Up Period, then in
each case the Lock-Up Period shall be extended and the restrictions imposed by this Agreement shall

 

 

continue to apply until the expiration of the 18-day period beginning on the date of the issuance
of the earnings release or the occurrence of the material news or material event.

     The restrictions set forth in the immediately preceding paragraph shall not apply to any
transfers made by the undersigned (i) as a bona fide gift to any member of the immediate family (as
defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the
undersigned or members of the undersigned’s immediate family, (ii) by will or intestate succession
upon the death of the undersigned, (iii) as a bona fide gift to a charity or educational
institution or (iv) by disposition of Common Stock or Beneficially Owned Shares pursuant to any
trading plan designed to meet the requirements of the safe harbor of Rule 10b5-1 under the
Securities Exchange Act of 1934, as amended, existing prior to the Lock-up Period or entered into
in renewal or replacement of such an existing plan upon its expiration on substantially similar
terms, provided, however, that in the case of any transfer described in clauses (i) and (ii) above,
it shall be a condition to the transfer that (A) the transferee executes and delivers to Houlihan,
not later than one business day prior to such transfer, a written agreement, in substantially the
form of this agreement (it being understood that any references to “immediate family” in the
agreement executed by such transferee shall expressly refer only to the immediate family of the
undersigned and not to the immediate family of the transferee) and otherwise satisfactory in form
and substance to Houlihan, and (B) if the undersigned is required to file a report under Section
16(a) of the Securities Exchange Act of 1934, as amended, reporting a reduction in beneficial
ownership of Common Stock or Beneficially Owned Shares or any securities convertible into or
exercisable or exchangeable for Common Stock or Beneficially Owned Shares during the Lock-Up Period
(as the same may be extended as described above), the undersigned shall include a statement in such
report to the effect that such transfer is being made as a gift or by will or intestate succession.
For purposes of this paragraph, “immediate family” shall mean a spouse, child, grandchild or other
lineal descendant (including by adoption), father, mother, father-in-law, mother-in-law, brother or
sister of the undersigned; and “affiliate” shall have the meaning set forth in Rule 405 under the
Securities Act of 1933, as amended.

     Any Common Stock or Beneficially Owned Shares acquired by the undersigned in the open market
after the date of this Agreement will not be subject to the restrictions set forth in this
agreement. After the date of this agreement, the undersigned may at any time enter into a written
plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended,
relating to the sale of Common Stock or Beneficially Owned Shares, if then permitted by the
Company, provided, however, that the shares subject to such plan shall be subject to the
restrictions set forth in this agreement.

     In order to enable this covenant to be enforced, the undersigned hereby consents to the
placing of legends or stop transfer instructions with the Company’s transfer agent with respect to
any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock.

     The undersigned further agrees that (i) it will not, during the Lock-Up Period (as the same
may be extended as described above), make any demand or request for or exercise any right with
respect to the registration under the Securities Act of 1933, as amended, of any Common Stock or
other Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable
for Common Stock or other Beneficially Owned Shares, and (ii) the

 

 

Company may, with respect to any Common Stock or other Beneficially Owned Shares or any securities
convertible into or exercisable or exchangeable for Common Stock or other Beneficially Owned Shares
owned or held (of record or beneficially) by the undersigned, cause the transfer agent or other
registrar to enter stop transfer instructions and implement stop transfer procedures with respect
to such securities during the Lock-Up Period (as the same may be extended as described above).

     The undersigned hereby represents and warrants that the undersigned has full power and
authority to enter into this agreement and that this agreement has been duly executed and delivered
by the undersigned and is a valid and binding agreement of the undersigned. This agreement and all
authority herein conferred are irrevocable and shall survive the death or incapacity of the
undersigned and shall be binding upon the undersigned and upon the heirs, personal representatives,
successors and assigns of the undersigned.

     The undersigned acknowledges and agrees that whether or not any offering of Common Stock
actually occurs depends on a number of factors, including market conditions. It is understood and
agreed that if (i) the Placement Agent Agreement is not executed by May 30, 2011, (ii) the Company
notifies you in writing that it does not intend to proceed with the offering of Common Stock, (iii)
the undersigned ceases to serve as an officer or director of the Company, or (iv) the Placement
Agent Agreement shall be terminated (other than the provisions that survive termination thereof)
prior to payment for and delivery of the securities to be sold pursuant thereto, the undersigned
shall be released from his or her obligations under the provisions of this agreement.

     This agreement shall be governed by, and construed in accordance with, the laws of the State
of New York.

	 	 	 	 	 
	 	Very truly yours,

 	 
	 	
 	 
	 	(Name of Stockholder — Please Print) 
	 
	 
	 
	 	
(Signature)

 	 
	 	
Address:exv10w2

Exhibit 10.2

FORM OF SUBSCRIPTION AGREEMENT

ThermoGenesis Corp.

2711 Citrus Road

Rancho Cordova, California 95742

Ladies and Gentlemen:

     The undersigned (the “Investor”) hereby confirms its agreement with ThermoGenesis Corp., a
Delaware corporation (the “Company”), as follows:

     1. This Subscription Agreement, including the Terms and Conditions for Purchase of Units
attached hereto as Annex I which are incorporated herein by this reference as if fully set
forth herein (the “Terms and Conditions” and, together with this Subscription Agreement, this
“Agreement”) is made as of the date set forth below between the Company and the Investor.

     2. The Company has authorized the sale and issuance to certain investors of up to an aggregate
of 2,250,000 units (the “Units”), each Unit consisting of (i) one (1) (each, a “Share” and,
collectively, the “Shares”) of common stock, par value $0.001 per share, of the Company (the
“Common Stock”), and (ii) one warrant (each, a “Warrant” and, collectively, the “Warrants”) to
purchase one-half share of Common Stock (and the fractional amount
being the “Warrant Ratio”), in
substantially the form attached hereto as Exhibit B, for a purchase price of $2.00 per Unit
(the “Purchase Price”). Units will not be issued or certificated and the Shares and Warrants are
immediately separable and will be issued separately. The shares of Common Stock issuable upon
exercise of the Warrants are referred to herein as the “Warrant Shares” and, together with the
Units, the Shares and the Warrants, are referred to herein as the “Securities”.

     3. The offering and sale of the Units (the “Offering”) are being made pursuant to (a) an
effective Registration Statement on Form S-3, No. 333-171563 (the “Registration Statement”) filed
by the Company with the Securities and Exchange Commission (the “Commission”), including the
Prospectus contained therein (the “Base Prospectus”), (b) if applicable, certain “free writing
prospectuses” (as that term is defined in Rule 405 under the Securities Act of 1933, as amended
(the “Act”)), that have been or will be filed, if required, with the Commission and delivered to
the Investor on or prior to the date hereof (the “Issuer Free Writing Prospectus”), containing only
certain supplemental information regarding the Units, the terms of the Offering and/or the Company,
and (c) a Prospectus Supplement (the “Prospectus Supplement” and, together with the Base
Prospectus, the “Prospectus”) containing certain supplemental information regarding the Securities
and terms of the Offering and the Company that has been or will be filed with the Commission and
has been delivered to the Investor prior to the Closing.

     4. The Company and the Investor agree that the Investor will purchase from the Company and the
Company will issue and sell to the Investor the number of Units set forth below (the “Investor
Units”) for the aggregate purchase price set forth below (the “Investor Purchase Price”). The
Investor Units shall be purchased pursuant to the Terms and Conditions.

 

 

The Investor acknowledges that the Offering is not being underwritten by the placement agent
named in the Prospectus Supplement and that there is no minimum offering amount.

     5. The manner of settlement of the Shares included in the Investor Units purchased by the
Investor (the “Investor Shares”) shall be as follows:

     Delivery by crediting the account of the Investor’s prime broker (as specified by such
Investor on Exhibit A annexed hereto) with the Depository Trust Company (“DTC”) through its
Deposit/Withdrawal At Custodian (“DWAC”) system, whereby Investor’s prime broker shall initiate a
DWAC transaction on the Closing Date using its DTC participant identification number, and released
by Computershare Investor Services, LLC, the Company’s transfer agent (the “Transfer Agent”), at
the Company’s direction. NO LATER THAN 8:00 A.M. (EASTERN TIME) ON THE FIRST BUSINESS DAY
IMMEDIATELY AFTER THE DATE OF EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, THE
INVESTOR SHALL:

	 	(I)	 	DIRECT THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE
CREDITED WITH THE INVESTOR SHARES ARE MAINTAINED TO SET UP A DWAC INSTRUCTING
THE TRANSFER AGENT TO CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE INVESTOR SHARES,
AND
	 
	 	(II)	 	REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE
AGGREGATE PURCHASE PRICE FOR THE INVESTOR UNITS BEING PURCHASED BY THE INVESTOR
TO THE FOLLOWING ACCOUNT:

Bank:                                                             

Beneficiary:                                                  

ABA:                                       
                    

Account Number:
                                      

BBK:                                         
                    

SWIFT:                                                  
      

IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR CONFIRM
THE PROPER ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF
DWAC IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE PURCHASE
PRICE FOR THE INVESTOR UNITS OR DOES NOT MAKE PROPER ARRANGEMENTS FOR SETTLEMENT IN
A TIMELY MANNER, THE SHARES AND THE WARRANTS MAY NOT BE DELIVERED AT CLOSING TO THE INVESTOR
OR THE INVESTOR MAY BE EXCLUDED FROM THE CLOSING ALTOGETHER.

     6. The executed Warrant shall be delivered in accordance with the terms thereof.

     7. The Investor represents that, except as set forth below, (a) it has had no position, office
or other material relationship within the past three years with the Company or persons known to it
to be affiliates of the Company, (b) it is not a member of the Financial Industry

 

 

Regulatory Authority, Inc. or an Associated Person (as such term is defined under the NASD
Membership and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor nor
any group of Investors (as identified in a public filing made with the Commission) of which the
Investor is a part in connection with the Offering of the Shares, acquired, or obtained the right
to acquire, 20% or more of the Common Stock (or securities convertible into or exercisable for
Common Stock) or the voting power of the Company on a post-transaction basis.

Exceptions:
                                                                     
           

(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

     7. The Investor represents that it has received (or otherwise had made available to it by the
filing by the Company of an electronic version thereof with the Commission) the Base Prospectus,
declared effective by the Commission on January 19, 2011, which is a part of the Company’s
Registration Statement and the documents incorporated by reference therein, any Issuer Free Writing
Prospectus and the Prospectus Supplement (collectively, the “Disclosure Package”), prior to or in
connection with the receipt of this Agreement. The Investor acknowledges that, prior to the
delivery of this Agreement to the Company, the Investor will receive certain additional information
regarding the Offering and the Company, including the pricing information (the “Offering
Information”). Such information may be provided to the Investor by any means permitted under the
Act, including the Prospectus Supplement, a free writing prospectus and oral communications. The
Investor acknowledges that the Disclosure Package contains information that may be material to the
Company and its securities that will not be disclosed to the public until the Company files a
Current Report on Form 8-K in accordance with Section 13 of Annex I hereto, and the
Investor agrees not to transact or agree to transact in the Company’s securities (other than as
contemplated by this Agreement) unless and until (a) the Company files a Current Report on Form 8-K
with the Commission in accordance with Section 13 of Annex I hereto and (b) The
Nasdaq Stock Market, LLC has opened for regular trading on March 7, 2011.

     8. No offer by the Investor to buy Investor Units will be accepted and no part of the Investor
Purchase Price will be delivered to the Company until the Investor has received or has public
access to the Disclosure Package and the Offering Information and the Company has accepted such
offer by countersigning a copy of this Agreement, and any such offer may be withdrawn or revoked,
without obligation or commitment of any kind, at any time prior to the Company (or the Agent (as
defined in the Terms and Conditions) on behalf of the Company) sending (orally, in writing or by
electronic mail) notice of its acceptance of such offer. An indication of interest will involve no
obligation or commitment of any kind until the Investor has been delivered the Disclosure Package
and Offering Information and this Agreement is accepted and countersigned by or on behalf of the
Company.

     9. For so long as any Warrants remain outstanding, the Company shall not, in any manner, issue
or sell any rights, warrants or options to subscribe for or purchase Common Stock that are directly
or indirectly convertible into or exchangeable for Common Stock at a price which resets as a
function of market price of the Common Stock at the time of such exercise, exchange or conversion.

 

 

Number of
Shares:                                         

Purchase Price Per Share: $                                        

Aggregate
Investor Purchase Price: $                    

     Please confirm that the foregoing correctly sets forth the agreement between us by signing in
the space provided below for that purpose.

	 	 	 	 	 	 	 	 

	 	 	Dated as of: March    , 2011
	 
	 	 	 	 	 	 
	 	 	 
	 	 	INVESTOR (print exact legal name)
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Print Authorized Signatory Name:
	 

	 	 	 	Title:	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Address:	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 

[Signature Page to ThermoGenesis Corp. Subscription Agreement]

 

 

Agreed and Accepted

this     day of March, 2011:

	 	 	 	 	 
	THERMOGENESIS CORP.

 	 	 
	By:  	 	 	 
	 	Name:  	 	 	 
	 	Title:  	 	 	 
	 

[Signature Page to ThermoGenesis Corp. Subscription Agreement]

 

 

ANNEX I

TERMS AND CONDITIONS FOR PURCHASE OF UNITS

     1. Authorization and Sale of the Units. Subject to the terms and conditions of this Agreement,
the Company has authorized the sale of the Units.

     2. Agreement to Sell and Purchase the Units; Agent.

     2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor,
and the Investor will purchase from the Company, upon the terms and conditions set forth herein,
the number of Units set forth on the last page of the Agreement to which these Terms and Conditions
for Purchase of Units are attached as Annex I (the “Signature Page”) for the aggregate
purchase price therefor set forth on the Signature Page.

     2.2 The Company anticipates that other investors (the “Other Investors”) will participate in
the Offering, and expects to complete sales of Units to them. The Company agrees that such Other
Investors will execute substantially the same form of Subscription Agreement as this Agreement. The
Investor and the Other Investors are hereinafter sometimes collectively referred to as the
“Investors,” and this Agreement and the Subscription Agreements executed by the Other Investors are
hereinafter sometimes collectively referred to as the “Agreements.”

     2.3 Investor acknowledges that the Company has agreed to pay Houlihan Lokey Capital, Inc. (the
“Agent”) a fee of 8.0%, including on the gross proceeds received by the Company from the exercise
of the Warrants (the “Placement Fee”).

     2.4 The Company has entered into a Placement Agent Agreement, dated the date hereof (the
“Placement Agreement”), with the Agent that contains certain representations, warranties, covenants
and agreements of the Company that may be relied upon by the Investor, which shall be a third party
beneficiary thereof.

     2.5 The Company covenants and agrees to use its reasonable best efforts to keep the
Registration Statement effective for as long as is needed to deliver freely tradable Warrant Shares
(as such term is defined in the Warrant to Purchase Common Stock entered into by the Company in
connection with the Offering).

     3. Closing and Delivery of the Units and Funds.

     3.1 Closing. The completion of the purchase and sale of the Units (the “Closing”)
shall occur at a place and time (the “Closing Date”) to be specified by the Company and the Agent,
and of which the Investors will be notified in advance by the Agent, in accordance with Rule 15c6-1
promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). At the
Closing, (a) the Company shall cause the Transfer Agent to deliver to the Investor the number of
Shares set forth on the Signature Page registered in the name of the Investor or, if so indicated
on the Investor Questionnaire attached hereto as Exhibit A, in the name of a nominee
designated by the Investor, (b) the Company shall cause to be delivered to the Investor a Warrant
to purchase a number of whole Warrant Shares determined by multiplying the number of Shares (and
Units) set forth on the signature page by the Warrant Ratio and rounding

 

 

up to the nearest whole number, and (c) the aggregate purchase price for the Units being
purchased by the Investor will be delivered by or on behalf of the Investor to the Company.

     3.2 Conditions to the Obligations of the Parties.

          (a) Conditions to the Company’s Obligations. The Company’s obligation to issue and
sell the Units to the Investor shall be subject to: (i) the receipt by the Company of the purchase
price for the Units being purchased hereunder as set forth on the Signature Page and (ii) the
accuracy of the representations and warranties made by the Investor and the fulfillment of those
undertakings of the Investor to be fulfilled prior to the Closing Date.

          (b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase
the Units will be subject to (x) the representations and warranties made by the Company in the
Agreements and the Placement Agreement shall be true and correct as of the date hereof and as of
the Closing Date and the Company shall have fulfilled those undertakings of the Company required to
be fulfilled prior to the Closing Date, as set forth in the Placement Agreement, and (y) that the
Agent shall not have: (i) terminated the Placement Agreement pursuant to the terms thereof or (ii)
determined that the conditions to the closing in the Placement Agreement have not been satisfied.
The Investor’s obligations are expressly not conditioned on the purchase by any or all of the Other
Investors of the Units that they have agreed to purchase from the Company. The Investor understands
and agrees that, in the event that the Agent, in its sole discretion determines that the conditions
to closing in the Placement Agreement have not been satisfied or if the Placement Agreement may be
terminated for any other reason permitted by the Placement Agreement, then the Agent may, but shall
not be obligated to, terminate the Placement Agreement, which shall have the effect of terminating
this Subscription Agreement pursuant to Section 14 below. The Agent shall not have the
authority to amend or modify the Company’s representations and warranties set forth in Section 3 of
the Placement Agreement or the closing conditions contained in Section 7 of the Placement Agreement
in a manner adverse to the Investor or waive any provisions or conditions contained therein without
the consent of the Investor.

     3.3 Delivery of Funds. BY NO LATER THAN 8:00 A.M. (EASTERN TIME) ON THE SECOND BUSINESS DAY
IMMEDIATELY AFTER THE DATE OF EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, the
Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for
the Investor Units being purchased by the Investor to the following account:

                                                            
           

Beneficiary:                                        
        

ABA:                                                             

Account Number:                                         

BBK:                                                             

SWIFT:                                                          

     3.4 Delivery of Shares. BY NO LATER THAN 8:00 A.M. (EASTERN TIME) ON THE SECOND BUSINESS DAY
IMMEDIATELY AFTER THE DATE OF EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, the

 

 

Investor shall direct the broker-dealer at which the account or accounts to be credited with
the Investor Shares are maintained, which broker/dealer shall be a DTC participant, to set up a DTC
Deposit/Withdrawal at Custodian (“DWAC”) instructing the Transfer Agent to credit such account or
accounts with the Shares. Such DWAC instruction shall indicate the settlement date for the deposit
of the Shares, which date shall be provided to the Investor by the Agent. Simultaneously with the
delivery to the Company of the funds, the Company shall direct the Transfer Agent to credit the
Investor’s account or accounts with the Investor Shares pursuant to the information contained in
the DWAC.

     4. Representations, Warranties and Covenants of the Investor.

     The Investor acknowledges, represents and warrants to, and agrees with, the Company and the
Agent, that:

     4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in securities presenting an investment
decision like that involved in the purchase of the Units, including investments in securities
issued by the Company and investments in comparable companies, (b) has answered all questions on
the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as
of the date hereof and will be true and correct as of the Closing Date and (c) in connection with
its decision to purchase the number of Units set forth on the Signature Page, has received and is
relying only upon the Disclosure Package and the documents incorporated by reference therein and
the Offering Information.

     4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by
the Company or the Agent that would permit an offering of the Units, or possession or distribution
of offering materials in connection with the issue of the Securities in any jurisdiction outside
the United States where action for that purpose is required, (b) if the Investor is outside the
United States, it will comply with all applicable laws and regulations in each foreign jurisdiction
in which it purchases, offers, sells or delivers Securities or has in its possession or distributes
any offering material, in all cases at its own expense and (c) the Agent is not authorized to make
and has not made any representation, disclosure or use of any information in connection with the
issue, placement, purchase and sale of the Units, except as set forth or incorporated by reference
in the Base Prospectus, the Prospectus Supplement or any Issuer Free Writing Prospectus.

     4.3 (a) The Investor has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken all necessary action
to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement
constitutes a valid and binding obligation of the Investor enforceable against the Investor in
accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of
equity (regardless of whether such enforceability is considered in a proceeding in equity or at
law) and except as to the enforceability of any rights to indemnification or contribution that may
be violative of the public policy underlying any law, rule or regulation (including any federal or
state securities law, rule or regulation).

 

 

     4.4 The Investor understands that nothing in this Agreement, the Prospectus, the Disclosure
Package, the Offering Information or any other materials presented to the Investor in connection
with the purchase and sale of the Units constitutes legal, tax or investment advice. The Investor
has consulted such legal, tax and investment advisors and made such investigation as it, in its
sole discretion, has deemed necessary or appropriate in connection with its purchase of Units.

     4.5 Since the date on which any Agent first contacted the Investor about the Offering, the
Investor has not disclosed any information regarding the Offering to any third parties (other than
its legal, accounting and other advisors) and has not engaged in any purchases or sales involving
the securities of the Company (including, without limitation, any Short Sales involving the
Company’s securities). The Investor covenants that it will not engage in any purchases or sales in
the securities of the Company (including Short Sales) or disclose any information about the
Offering (other than to its advisors that are under a legal obligation of confidentiality) prior to
the time that the transactions contemplated by this Agreement are publicly disclosed. The Investor
agrees that it will not use any of the Securities acquired pursuant to this Agreement to cover any
short position in the Common Stock if doing so would be in violation of applicable securities laws.
For purposes hereof, “Short Sales” include, without limitation, all “short sales” as defined in
Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box,
and all types of direct and indirect stock pledges, forward sales contracts, options, puts, calls,
short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act)
and similar arrangements (including on a total return basis), and sales and other transactions
through non-US broker dealers or foreign regulated brokers.

     5. Survival of Representations, Warranties and Agreements. Notwithstanding any investigation
made by any party to this Agreement or by the Agent, all covenants, agreements, representations and
warranties made by the Company and the Investor herein will survive the execution of this
Agreement, the delivery to the Investor of the Shares and the Warrants being purchased and the
payment therefor.

     6. Notices. All notices, requests, consents and other communications hereunder will be in
writing, will be mailed (a) if within the domestic United States by first-class registered or
certified airmail, or nationally recognized overnight express courier, postage prepaid, or by
facsimile or (b) if delivered from outside the United States, by International Federal Express or
facsimile, and (c) will be deemed given (i) if delivered by first-class registered or certified
mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized
overnight carrier, one business day after so mailed, (iii) if delivered by International Federal
Express, two business days after so mailed and (iv) if delivered by facsimile, upon electronic
confirmation of receipt and will be delivered and addressed as follows:

          (a) if to the Company, to:

ThermoGenesis Corp.

2711 Citrus Road

Rancho Cordova, California 95742

Attention: Matthew T. Plavan, CFO & EVP, Business Development

Fax: (916) 858-5197

 

 

with a copy to:

Weintraub Genshlea Chediak

400 Capitol Mall, Eleventh Floor

Sacramento, CA 95816

Attention: David C. Adams.

Facsimile: (916) 446-1611

          (b) if to the Investor, at its address on the Signature Page hereto, or at such other address
or addresses as may have been furnished to the Company in writing.

     7. Changes. This Agreement may not be modified or amended except pursuant to an instrument in
writing signed by the Company and the Investor.

     8. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this Agreement.

     9. Severability. In case any provision contained in this Agreement should be invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein will not in any way be affected or impaired thereby.

     10. Governing Law. This Agreement will be governed by, and construed in accordance with, the
internal laws of the State of New York, without giving effect to the principles of conflicts of law
that would require the application of the laws of any other jurisdiction.

     11. Counterparts. This Agreement may be executed in two or more counterparts, each of which
will constitute an original, but all of which, when taken together, will constitute but one
instrument, and will become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties. The Company and the Investor acknowledge and agree that
the Company shall deliver its counterpart to the Investor along with the Prospectus Supplement (or
the filing by the Company of an electronic version thereof with the Commission).

     12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s receipt of
the Company’s signed counterpart to this Agreement, together with the Prospectus Supplement (or the
filing by the Company of an electronic version thereof with the Commission), shall constitute
written confirmation of the Company’s sale of Units to such Investor.

     13. Press Release and 8-Ks. The Company and the Investor agree that the Company shall, prior
to the opening of the financial markets in New York City on the business day immediately after the
date hereof, (a) issue a press release announcing the Offering and disclosing all material
information regarding the Offering, (b) file a Current Report on Form 8-K with the Commission
including a form of this Agreement and the Placement Agreement as

 

 

exhibits thereto, which such Current Report on Form 8-K shall include all material information
regarding the Offering, and (c) if applicable, file another Current Report on Form 8-K with the
Commission disclosing any other material information regarding the Company that is contained in the
Disclosure Package. Notwithstanding the foregoing, the Company shall not publicly disclose the name
of the Investor or any affiliate or investment adviser of the Investor, or include the name of the
Investor or any affiliate or investment adviser of any Investor in any press release or filing with
the Commission or any regulatory agency or trading market, without the prior written consent of
such Investor, except (i) as required by federal securities law and (ii) to the extent such
disclosure is required by law or trading market regulations, in which case the Company shall
provide the Investor with prior written notice of such disclosure permitted under this sub-clause
(ii). As of the filing of the Form 8-Ks referred to in clauses (b) and (c) described above, the
Investor shall not be in possession of any material, non public information received from the
Company, any subsidiary of the Company or any of their respective officers, directors or employees
in connection with the Offering.

     14. Termination. In the event that the Placement Agreement is terminated by the Agent pursuant
to the terms thereof, this Agreement shall terminate without any further action on the part of the
parties hereto. The Investor shall have the right to terminate this agreement if the Closing has
not occurred on or before March 11, 2011.

     15. Maximum Offering Amount. The Company hereby covenants and agrees that the aggregate
purchase price of the Units to be sold in this offering shall not exceed $4.5 million.

     16. Participation in Future Financing. From the date hereof until the date that is eighteen
(18) months after the Closing Date (except, with respect to any initial purchaser of Units in this
offering (each, a “Purchaser”), to the extent that at such time such Purchaser does not
beneficially own at least 35% of the Common Stock (as determined on an as-exercised basis without
regard to any limitations on exercise of the Warrants) purchased by such Purchaser in this
offering), neither the Company nor any of its Subsidiaries shall, directly or indirectly, effect
any Subsequent Placement (as defined below) unless the Company shall have first complied with this
Section 16. The Company acknowledges and agrees that the right set forth in this Section 16 is a
right granted by the Company, separately, to each Purchaser.

     16.1 At least ten (10) Trading Days (as defined in the Warrant) prior to the pricing of any
proposed or intended Subsequent Placement, the Company shall deliver to each Purchaser a written
notice of its proposal or intention to effect a Subsequent Placement (each such notice, a
“Pre-Notice”), which Pre-Notice shall not contain any information (including, without limitation,
material, non-public information) other than: (i) a statement that the Company proposes or intends
to effect a Subsequent Placement, and (ii) a statement informing such Purchaser that it is entitled
to receive an Offer Notice (as defined below) with respect to such Subsequent Placement upon its
written request. Upon the written request of a Purchaser within three (3) Trading Days after the
Company’s delivery to such Purchaser of such Pre-Notice, and only upon a written request by such
Purchaser, the Company shall promptly, but no later than two (2) Trading Days after such request,
deliver to such Purchaser a written notice (the “Offer Notice”) of any proposed or intended
issuance or sale or exchange (the “Offer”) of the securities being offered (the “Offered
Securities”) in a Subsequent Placement, which Offer Notice shall (w) identify and describe the
Offered Securities (to the extent then known), (x) describe the price

 

 

and other terms (to the extent then known) upon which they are to be issued, sold or
exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (y)
identify the Persons (if known) to which or with which the Offered Securities are to be offered,
issued, sold or exchanged and (z) offer to issue and sell to or exchange with such Purchaser in
accordance with the terms of the Offer such Purchaser’s pro rata portion of the lesser of (x) 50%
of the Offered Securities and (y) such Offered Securities with an aggregate purchase price of $9
million, provided that the number of Offered Securities which such Purchaser shall have the right
to subscribe for under this Section 16 shall be (a) based on such Purchaser’s pro rata portion of
the aggregate Purchase Price of the Units purchased hereunder by all Purchasers (the “Basic
Amount”), and (b) with respect to each Purchaser that elects to purchase its Basic Amount, any
additional portion of the Offered Securities attributable to the Basic Amounts of other Purchasers
as such Purchaser shall indicate it will purchase or acquire should the other Purchasers subscribe
for less than their Basic Amounts (the “Undersubscription Amount”).

     16.2 To accept an Offer, in whole or in part, such Purchaser must deliver a written notice to
the Company prior to the end of the third (3rd) Business Day (as defined in the Warrant) after such
Purchaser’s receipt of the Offer Notice (the “Offer Period”), setting forth the portion of such
Purchaser’s Basic Amount that such Purchaser elects to purchase and, if such Purchaser shall elect
to purchase all of its Basic Amount, the Undersubscription Amount, if any, that such Purchaser
elects to purchase (in either case, the “Notice of Acceptance”). If the Basic Amounts subscribed
for by all Purchasers are less than the total of all of the Basic Amounts, then such Purchaser who
has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to
purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it has
subscribed for; provided, however, if the Undersubscription Amounts subscribed for exceed the
difference between the total of all the Basic Amounts and the Basic Amounts subscribed for (the
“Available Undersubscription Amount”), such Purchaser who has subscribed for any Undersubscription
Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as
the Basic Amount of such Purchaser bears to the total Basic Amounts of all Purchasers that have
subscribed for Undersubscription Amounts, subject to rounding by the Company to the extent it deems
reasonably necessary. Notwithstanding the foregoing, if the Company desires to modify or amend the
terms and conditions of the Offer prior to the expiration of the Offer Period, the Company may
deliver to each Purchaser a new Offer Notice and the Offer Period shall expire on the third (3rd)
Business Day after such Purchaser’s receipt of such new Offer Notice.

     16.3 The Company shall have five (5) Business Days from the expiration of the Offer Period
above (i) to offer, issue, sell or exchange all or any part of such Offered Securities as to which
a Notice of Acceptance has not been given by a Purchaser (the “Refused Securities”) pursuant to a
definitive agreement(s) (the “Subsequent Placement Agreement”), but only to the offerees described
in the Offer Notice (if so described therein) and only upon terms and conditions (including,
without limitation, unit prices and interest rates) that are not more favorable to the acquiring
Person or Persons or less favorable to the Company than those set forth in the Offer Notice. The
Company agrees to make a public announcement (through a press release or a Current Report on Form
8-K filed with the SEC) of the final pricing of the transactions contemplated by such Subsequent
Placement Agreement within one (1) business day after the consummation of such pricing.

 

 

     16.4 In the event the Company shall propose to sell less than all the Refused Securities (any
such sale to be in the manner and on the terms specified in Section 16.3 above), then such
Purchaser may, at its sole option and in its sole discretion, reduce the number or amount of the
Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than
the number or amount of the Offered Securities that such Purchaser elected to purchase pursuant to
Section 16.2 above multiplied by a fraction, (i) the numerator of which shall be the number or
amount of Offered Securities the Company actually proposes to issue, sell or exchange (including
Offered Securities to be issued or sold to Purchasers pursuant to this Section 16 prior to such
reduction) and (ii) the denominator of which shall be the original amount of the Offered
Securities. In the event that any Purchaser so elects to reduce the number or amount of Offered
Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more
than the reduced number or amount of the Offered Securities unless and until such securities have
again been offered to the Purchasers in accordance with Section 16.1 above.

     16.5 Upon the closing of the issuance, sale or exchange of all or less than all of the Refused
Securities, such Purchaser shall acquire from the Company, and the Company shall issue to such
Purchaser, the number or amount of Offered Securities specified in its Notice of Acceptance. The
purchase by such Purchaser of any Offered Securities is subject in all cases to the preparation,
execution and delivery by the Company and such Purchaser of a separate purchase agreement relating
to such Offered Securities reasonably satisfactory in form and substance to such Purchaser and its
counsel.

     16.6 Any Offered Securities not acquired by a Purchaser or other Persons in accordance with
this Section 16 may not be issued, sold or exchanged until they are again offered to such Purchaser
under the procedures specified in this Agreement.

     16.7 The Company and each Purchaser agree that if any Purchaser elects to participate in the
Offer, neither the Subsequent Placement Agreement with respect to such Offer nor any other
transaction documents related thereto (collectively, the “Subsequent Placement Documents”) shall
include any term or provision whereby such Purchaser shall be required to agree to any restrictions
on trading as to any securities of the Company (other than restrictions that may be imposed under
federal or state securities laws) that are not also applicable to other participants in the
Subsequent Placement or be required to consent to any amendment to or termination of, or grant any
waiver, release or the like under or in connection with, any agreement previously entered into with
the Company or any instrument received from the Company.

     16.8 Notwithstanding anything to the contrary in this Section 16 and unless otherwise agreed
to by such Purchaser, the Company shall either confirm in writing to such Purchaser that the
transaction with respect to the Subsequent Placement has been abandoned or shall publicly disclose
its intention to issue the Offered Securities, in either case, in such a manner such that such
Purchaser will not be in possession of any material, non-public information, by the tenth (10th)
Business Day following delivery of the Offer Notice. If by such tenth (10th) Business Day, no
public disclosure regarding a transaction with respect to the Offered Securities has been made, and
no notice regarding the abandonment of such transaction has been received by such Purchaser, such
transaction shall have been abandoned and such Purchaser shall not be in possession of any
material, non-public information with respect to the Company or any of its

 

 

Subsidiaries. Should the Company decide to pursue such transaction with respect to the Offered
Securities, the Company shall provide such Purchaser with another Offer Notice and such Purchaser
will again have the right of participation set forth in this Section 16. The Company shall not be
permitted to deliver more than one such Offer Notice to such Purchaser in any sixty (60) day
period, except as expressly contemplated by the last sentence of Section 16.2.

     16.9 The restrictions contained in this Section 16 shall not apply in connection with the
issuance of any Excluded Securities (as defined below). The Company shall not circumvent the
provisions of this Section 16 by providing terms or conditions to one Purchaser that are not
provided to all.

     16.10 For the purposes of this Section 16, the following definitions will apply:

          (a) “Approved Stock Plan” means any equity incentive or benefit plan or agreement providing
for the issuance of shares of Common Stock, options, stock bonuses, other equity-based awards,
warrants or other similar arrangements, to employees, officers, directors or consultants to the
Company or any subsidiary, which has been approved by the Board of Directors of the Company.

          (b) “Convertible Securities” means any shares or securities (other than Options) directly or
indirectly convertible into or exercisable or exchangeable for shares of Common Stock.

          (c) “Excluded Securities” means, collectively: (A) any shares of Common Stock issued or
issuable in connection with any Approved Stock Plan; (B) any shares of Common Stock issued or
issuable in connection with any securities issued pursuant to the Subscription Agreements and
securities issued upon the exercise or conversion of those securities; (C) any shares of Common
Stock issued or issuable in connection with any upon conversion, exercise or exchange of any
Options or Convertible Securities which are outstanding on the day immediately preceding the
Closing Date, provided such securities are not amended after the date hereof to increase the number
of shares of Common Shares issuable thereunder or to lower the exercise or conversion price
thereof; (D) any shares of Common Stock issued by reason of a dividend, stock split or other
distribution on shares of Common Stock; (E) any shares of Common Stock or other securities issued
or issuable to vendors, parties providing the Company with equipment leases, real property leases,
loans, credit lines, guaranties of indebtedness, cash price reductions or similar financing; any
shares of Common Stock or other securities issued or issuable in bona fide transactions with
strategic business partners or other third parties with which the Company or any subsidiary has a
business relationship (if in transaction with primarily non-financing purposes); (F) any shares of
Common Stock or other securities issued or issuable in connection with a bona fide business
acquisition by the Company of another corporation, entity or business, whether by merger,
consolidation, sale or purchase of assets, sale or exchange of stock or otherwise; or (G) any
shares of Common Stock or other securities issued or issuable in consideration of the acquisition
or in-licensing of intellectual property rights, products or technologies; provided, that with
respect to clauses (E), (F) and (G) above, the primary purpose of such issuance is not to raise
capital.

 

 

          (d) “Options” means any rights, warrants or options to subscribe for or purchase shares of
Common Stock or Convertible Securities.

          (e) “Subsequent Placement” means the sale, grant of any option to purchase, or other
disposition of by the Company, directly or indirectly, of any of the Company’s or its Subsidiaries’
equity or equity equivalent securities, including, without limitation, any convertible debt,
preferred stock or other instrument or security that is, at any time during its life and under any
circumstances, convertible into or exchangeable or exercisable for shares of Common Stock or
Convertible Securities or Options.

 

 

EXHIBIT A TO SUBSCRIPTION AGREEMENT

THERMOGENESIS CORP.

INVESTOR QUESTIONNAIRE

Pursuant to Section 3 of Annex I to the Agreement, please provide us with the
following information:

	1.	 	The exact name that your Shares and Warrants are to be registered in. You may
use a nominee name if appropriate:
	 
	2.	 	The relationship between the Investor and the registered holder listed in
response to item 1 above:
	 
	3.	 	The mailing address of the registered holder listed in response to item 1 above:
	 
	4.	 	The Social Security Number or Tax Identification Number of the registered
holder listed in the response to item 1 above:
	 
	5.	 	Name of DTC Participant (broker-dealer at which the account or accounts to be
credited with the Shares are maintained):
	 
	6.	 	DTC Participant Number:
	 
	7.	 	Name of Account at DTC Participant being credited with the Shares:
	 
	8.	 	Account Number at DTC Participant being credited with the Shares.

 

 

EXHIBIT B TO SUBSCRIPTION AGREEMENT

FORM OF WARRANT

See Exhibit 4.1 filed herein.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]